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Background: The PI3K/AKT/mTOR signaling pathway has been impli-
cated in multiple cancers, and as a regulator of many key oncogenic 
processes. Our studies implicate a role for this pathway in resistance to 
both targeted and immune therapies for melanoma.
Materials and methods: Melanoma cell lines and clinical specimens 
were utilized to study the significance and functional consequences of 
the PI3K/AKT/mTOR pathway. Analyses of clinical specimens were per-
formed under institution review board-approved protocols.
Results: Pilot whole genome expression profiling and synthetic 
lethality screens implicated oxidative phosphorylation (OxPhos) 
in resistance to BRAF and MEK inhibitors in BRAF-mutant human 
melanoma cell lines. Characterization of panels of human cell lines 
with de novo or acquired resistance to MAPK pathway inhibitors 
demonstrated that ~50  % of the cell lines exhibited a high OxPhos 
phenotype. The presence of high OxPhos correlated with increased 
expression of PGC1-alpha and with sensitivity to combined inhibition 
of the MAPK pathway and mTORC1/2. mTORC1/2 inhibition caused 
cytoplasmic sequestration of MITF and subsequent decreased expres-
sion of MITF-regulated genes, including PGC1-alpha. In vitro test-
ing demonstrated that a direct OxPhos inhibitor similarly achieved 
growth inhibition and apoptosis in some human melanoma cell 
lines with high OxPhos. Further, the OxPhos inhibitor abrogated the 
growth of inhibitor-resistant BRAF mutant human melanoma cell 
lines in  vivo. Activation of the PI3K/AKT/mTOR pathway by loss of 
PTEN was also shown to promote resistance to T cell mediated cell 
killing in  vitro and in  vivo. Loss of PTEN correlated with decreased 
CD8 cell infiltrates in clinical specimens and increased expression of 
immunosuppressive cytokines. While pan-PI3K inhibitors inhibited 
immune cell viability and function, isoform-selective inhibitors did 
not significantly affect immune function and they produced synergy 
with immunotherapy.
Conclusions: The PI3K/AKT/mTOR signaling pathway is an important 
regulator of key cellular processes in melanoma, and should be con-
sidered as a candidate combinatorial partner for both targeted and 
immune therapies.
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Background: Approximately 50 % of melanoma patients present activat-
ing mutations in the BRAF oncogene. For these patients new therapeutic 
options have been made available in recent years represented by BRAF 
and MEK kinase inhibitors (KIs). However, the main issue remains the 
development of drug resistance, which is responsible for disease relapse 
within months after treatment. Established drug resistance is caused in 
most cases by several gene mutations which either reactivate the MAPK/
ERK pathway or involve activation of receptor tyrosine kinase driven sur-
vival pathways. However, besides mutational events it is emerging that 
a wealth of adaptive changes take place in melanoma cells after drug 
exposure which heavily contribute to the development of resistance. 
Our group has focused its attention over the past years to some of these 
adaptive changes in the search of new therapeutic targets.
Materials and methods: Up to ten melanoma cell lines bearing differ-
ent mutations in the BRAF gene were exposed to BRAFi and/or MEKi 
from 2 to 72  h and harvested for protein and RNA extraction. Drug 
resistant melanoma cell populations were selected using increasing 
drug concentrations over a 2  months period. Activation of RTKs and 
intracellular signaling was assesses by RTK arrays and western blot-
ting. ErbB3 receptor was inhibited by monoclonal antibodies A3 and 
A4. Changes in miRNA levels were detected by Nanostring technology 
or by RT-PCR. Tumor biopsies were obtained from patients before KI 
therapy or after relapse and used for RNA extraction.
Results: We first showed that ErbB3 is the main receptor to be phos-
phorylated after short term exposure to KIs in different melanoma 
lines. ErbB3 activation and in turn AKT phosphorylation depends on 
an autocrine loop due to increased neuregulin-1 production. Anti-
ErbB3 mAbs cause receptor internalization and degradation and 
potentiate the growth inhibitory effect of BRAFi and MEKi in vitro and 
in vivo. Most importantly mAbs-induced ErbB3 inhibition impairs the 
development of resistance in  vitro and tumor relapse in  vivo after 
therapy discontinuation. More recently we focused our attention on 
microRNA deregulations after drug exposure of melanoma cells. Our 
preliminary data show the involvement of a network of miRNAs on the 
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Conclusions: Melanoma cells bearing activating BRAF mutations 
undergo a series of adaptive changes after exposure to drugs that 
inhibit the MAPK pathway, which help them to survive and help the 
development resistance. Identification of these adaptive changes is 
leading to identification of new targets for intervention.
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Background: Growing evidence has emerged that a subset of mela-
noma patients shows signs for spontaneous anti-tumor immune 
responses and T cell infiltration into tumor sites, which represents 
an important prognostic value and which is associated with clinical 
responses to immunotherapies. However, the underlying molecular 
mechanisms that can explain the absence of a T cell response in the 
majority of patients are not defined.
Results: Exome sequencing and gene expression profiling of melanoma 
biopsies revealed activation of β-catenin in a major subset of non-T cell-
infiltrated tumors. Using an inducible autochthonous mouse melanoma 
model (BrafV600E/PTEN−/− ± CAT-STA+; BP and BPC) we herein demon-
strate a causal effect between tumor-intrinsic active β-catenin sign-
aling and T cell exclusion. Mechanistic studies revealed a lack of T cell 
priming against tumor-associated antigens in the context of β-catenin-
expressing tumors. In-depth analysis indicated that absence of T cells 
was caused by defective recruitment of CD103+ dermal dendritic cells, 
due to repressed expression of the chemokine CCL4. Tumors express-
ing active β-catenin were resistant to therapy with anti-CTLA-4/anti-
PD-L1 antibodies, mimicking the phenotype observed in humans. The 
absence of CD103+ dendritic cells led to defective early T cell priming 
and absence of systemic immunity. However, whether tumor-intrinsic 
β-catenin signaling is responsible for mediating tumor resistance even 
after an anti-tumor T cell response is established remains elusive. To 
test this notion, we used the spontaneously rejected tumor cell line 
MC57.SIY, which is known to induce an immunologic memory mediat-
ing immune surveillance. Following rejection of MC57.SIY in BP-SIY and 
BPC-SIY autochthonous tumors were induced. Although the primary 
SIY-specific CD8+ T cell response and the induced memory response 
were comparable between both tumor models, tumor protection was 
observed against BP-SIY tumors, whereas it was absent in BPC-SIY 
tumors. This increased tumor control in BP-SIY mice was accompanied 
by strong T cell infiltration and a boosted memory response. These 
results suggest that tumor-intrinsic β-catenin signaling might also be 
responsible for the observed exclusion of migrating effector T cells into 
the tumor site.
Conclusion: Taken together, these data provide strong evidence that 
up-regulation of β-catenin in tumor cells is a very potent mechanism of 
immune evasion against not only a primary immune response, but also 
against an immunologic memory. Moreover, tumor-intrinsic β-catenin 
activation likely mediates resistance not only to checkpoint blockade 
therapy but also to T cell adoptive transfer. Future studies will focus on 
therapeutic solutions targeting the activated β-catenin pathway with 
the intention to allow inflammation into this subset of tumors.
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It is generally assumed that in order to be used as targets of antibody- 
based immunotherapy of malignant diseases, tumor antigens have to 
be expressed on the plasma membrane of tumor cells. This assump-
tion has markedly reduced the number of tumor antigens which can 
be targeted with antibody-based immunotherapy, since only a few of 
the molecules expressed on the plasma membrane of tumor cells meet 
the criteria required to be used as targets of antibody-based immuno-
therapy. Intracellular TAs which analyses with T cells have shown to 
be much more diverse than those expressed on plasma membrane, 
have been excluded from studies to identify targets of antibody-based 
immunotherapy for the treatment of malignant diseases.
We have hypothesized that, under certain experimental conditions and 
especially in malignant cells, intracellular molecules may migrate to cell 
surface and become accessible to interact with the corresponding anti-
bodies. Our hypothesis is supported by the isolation of the human mon-
oclonal antibody (mAb) W9, which recognizes an extracellular epitope 
of the intracellular chaperone molecule glucose regulated protein of 
94,000 Da (Grp94). The mAb W9 defined Grp94 epitope is expressed on 
various types of malignant cells including melanoma. In several types 
of cancer, the mAb W9 defined Grp94 epitope is expressed not only on 
differentiated cancer cells, but also on cancer initiating cells (CICs). The 
mAb W9 defined Grp94 epitope is upregulated on BRAFV600E melanoma 
cells by incubation with BRAF inhibitor, and with chemotherapeutic 
agents. In contrast, the mAb W9 defined Grp94 epitope is not detecta-
ble on normal cells. Therefore it represents an attractive target to imple-
ment antibody-based immunotherapy of various types of solid tumors.
In this study we have investigated the in vitro and in vivo anti-tumor 
activity of mAb W9 utilizing malignant melanoma as a model. The 
results obtained indicate that mAb W9 inhibits the growth of mela-
noma cells. This effect reflects the induction of apoptosis as well as 
the inhibition of several signaling pathways including Erk, Akt and 
FAK pathways. The anti-tumor activity of mAb W9 is enhanced by the 
small molecule LDE225, an inhibitor of SHH pathway. Furthermore, 
mAb W9 delays the development of BRAF inhibitor resistance in mela-
noma cells with mutant BRAF. Lastly, mAb W9 induces the regression 
of experimental lung metastasis established in immunodeficient mice 
by intravenous injection of melanoma M21 cells.
If representative of a general phenomenon, these results suggest that 
intracellular tumor antigens may be a useful source of targets for anti-
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Recent successes of cancer immunotherapy have demonstrated the 
power of anti-tumor T cells to change outcome of metastatic disease 
and are transforming cancer treatment. Two key observations have 
emerged from clinical studies. The first is that a fraction of patients 
with metastatic disease possesses a sufficient number and repertoire 
of tumor-reactive T cells that can be unleashed by immune checkpoint 
blockade to cause tumor regression [1]. The second is that unique 
mutated proteins expressed by an individual tumor are a source of 
powerful tumor-specific T cell antigens [2]. An outstanding challenge 
is to devise novel strategies to vaccinate the vast majority of cancer 
patients who do not respond to immune checkpoint blockade against 
their own individual tumor.
Local tumor radiotherapy is increasingly considered an appealing strat-
egy to achieve personalized vaccination, and we have shown that it 
can convert tumors refractory to immune checkpoint inhibitors into 
Page 3 of 27  J Transl Med 2016, 14(Suppl 1):S65
responsive ones by breaking down the barriers to immune cell infiltra-
tion and promoting development of anti-tumor T cells [3–5]. These pro-
immunogenic effects of radiation are modulated by the pre-existing 
tumor microenvironment, and are dependent on the dose and fractiona-
tion of radiation employed [6, 7]. Immunogenic cell death is induced by 
radiation in a dose-dependent way, with higher ablative single doses 
being more effective in vitro [8]. However, in vivo the pro-immunogenic 
effects of radiation are countered by generation of immunosuppres-
sive mediators. We have recently identified a critical role of transform-
ing growth factor beta (TGFβ) in regulating development of anti-tumor 
T cells and tumor rejection following radiotherapy [9]. We are currently 
investigating the role of other TGFβ family members, as well as aden-
osinergic pathways in regulating the shift between immune activa-
tion and immune suppression in the tumor following radiotherapy. The 
overarching goal of our work is to define radiation interactions with the 
microenvironment of a given tumor, and devise a personalized approach 
to optimize in situ vaccination by radiation. Results of these studies will 
improve the design of clinical trials testing radiation in combination with 
immune checkpoint inhibitors and other immunotherapies.
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Immune checkpoint blockade results in impressive clinical responses. 
However, only a minority of patients benefit from such therapies. It 
is urgently desired to understand the mechanisms, and more impor-
tantly, to find approaches that can overcome tumor resistance to 
checkpoint blockade. Several clinical studies have shown strong cor-
relations between a spontaneous T cell-inflamed tumor microenviron-
ment and responses to checkpoint blockade. However, majority of 
established tumors are non-T cell-inflamed and resist to such immu-
notherapies. It raises possibility that preexisting T cells inside tumor 
tissues is essential for checkpoint blockade. Here we demonstrate 
that sufficient T cell infiltration in tumor tissues is a prerequisite for the 
response to PD-L1 blockade. Targeting tumors with tumor necrosis 
factor superfamily member LIGHT activates lymphotoxin beta recep-
tor signaling, leading to the production of chemokines that recruit 
massive numbers of T cells. Furthermore, targeting non-T cell-inflamed 
tumor tissues by antibody-guided LIGHT creates a T cell-inflamed 
microenvironment and overcomes tumor resistance to checkpoint 
blockade. Our study indicates that targeting tumor with LIGHT may be 
an effective strategy for non-T cell-inflamed tumors which are resistant 
to checkpoint blockades.
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Melanoma includes a group of genetically and clinically district malig-
nancies derived from the neural crest. UV-light contributes signifi-
cantly. It is the major cause for genetical alterations. The mutation load 
is also relevant for immune responses. In addition, there are a number 
of driver mutations that can be targeted by small molecules. In this 
context melanoma is a paradigm for precision medicine. Biomarkers 
are essential in this context and will get more and more important for 
clinical treatment decisions.
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Background: T-VEC is an HSV-derived oncolytic immunotherapy 
designed to induce systemic antitumor immunity. In a phase 3 mela-
noma study, T-VEC monotherapy demonstrated a significantly higher 
durable response rate (DRR, ≥6  months response) vs GM-CSF (Andt-
backa et  al. ASCO 2013). Combining T-VEC to promote release of 
tumor-derived antigens with an immune checkpoint inhibitor such 
as ipi to improve T cell responses may enhance efficacy compared to 
either alone. The phase 1b portion of this phase 1b/2 combination 
study (NCT01740297) completed enrollment and met its primary 
objective with no dose limiting toxicities and objective response rate 
(ORR) of 56 % (Puzanov et al. ASCO 2014).
Materials and methods: Key criteria: Stage IIIB-IV melanoma, no prior 
systemic tx, measurable disease, and ≥1 injectable cutaneous, subcutane-
ous, or nodal lesion. T-VEC was given intralesionally at ≤4 mL of 106 PFU/
mL at week 1, then 108 PFU/mL at week 4 and then q2w. Ipi 3 mg/kg q3w 
was given as four infusions starting week 6. T-VEC continued until DLT, 
intolerance, all injectable tumors disappeared, or disease progression (PD) 
per immune-related response criteria (irRC). Blood was collected at weeks 
1, 4, 6, 9, 15, and after tx completion and tumor assessments Q12W.
Results: Data cutoff was 22 Dec 2014 with all pts ≥17  months from 
start of tx. Of 18 pts receiving T-VEC + ipi, treatment-emergent gr 3/4 
AEs occurred in 32 % and gr 3/4 immune-related AEs in two pts with 
no treatment-related deaths. Per irRC, ORR: 56 % (33 % CR), DRR: 44 %. 
Median time to response: 5.3  months (range 2.6–5.7). Median pro-
gression free survival (PFS): 10.6 months (2.6−19.3+). Median overall 
survival (OS) was not reached with 12 and 18 months survival at 72.2 
and 67  %. On a lesion level, 24 and 11 of 35 injected index lesions 
and 8 and 5 of 16 uninjected index lesions regressed ≥50 and 100 %, 
respectively. Higher antibody (ab) titers to MAGEA3 occurred more fre-
quently during tx in responders, but ab to 27 other melanoma-associ-
ated antigens showed less distinct changes.
Conclusions: At >17  months, TVEC +  ipi continued to demonstrate 
durable responses with 2/3 of pts alive at 18  months and no new 
safety signals. Phase 2 (ipi vs T-VEC +  ipi) is ongoing and Phase Ib/III 
study of T-VEC + pembrolizumab has been started.
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Immune checkpoint blockade with agents such as ipilimumab, pem-
brolizumab, and nivolumab has dramatically changed the outlook 
for patients with metastatic melanoma. Several studies have inves-
tigated the combination of various checkpoint blocking antibodies 
such as the combination of ipilimumab and nivolumab and the com-
bination of ipilimumab and pembrolizumab. We await overall survival 
data from phase III studies to determine the true values of combining 
immune checkpoint inhibitors. Nonetheless, combinations have dem-
onstrated impressive objective response rates and progression free 
survival. In this talk, we will discuss the available data for combining 
immune checkpoint inhibitors, side effects, and future directions.
News in immunotherapy
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Patients with Stages IIB-C/III/IV melanoma that surgically resectable 
carry a high risk for melanoma recurrence and death from melanoma 
with surgical management alone. Systemic adjuvant therapy of targets 
melanoma micrometastases and is indicated postoperatively where 
it may provide the greatest opportunity for cure before relapse into 
advanced inoperable stages. Multiple systemic therapeutic agents have 
been tested as adjuvant therapy for melanoma with durable benefits 
seen with interferon-α (IFN). In randomized clinical trials, IFNα has been 
tested as part of various regimens that vary by dose, duration, route of 
administration and formulation. Several randomized trials and three 
major meta-analyses have demonstrated a reproducible and signifi-
cant impact on relapse free survival (RFS). Overall survival benefit was 
seen only in two of the three ECOG and U.S. Intergroup trials that tested 
the 1  year high dose regimen as compared to observation (E1684) 
and the GMK vaccine (E1694). Pegylated IFN was shown to improve 
RFS as tested in the EORTC 18,991 trial. Recently reported adjuvant tri-
als include the phase III EORTC 18,071 trial that tested ipilimumab at 
10 mg/kg versus placebo and has met it primary endpoint of RFS. The 
U.S. Intergroup E1609 trial is expected to inform the field on the clinical 
efficacy of ipilimumab versus interferon alfa-2b in the high-risk adju-
vant setting, as well as the risk-to-benefit ratio of the two ipilimumab 
dosages (3 and 10 mg/kg) tested. Trials testing adjuvant therapy with 
the anti-PD1 antibodies pembrolizumab and nivolumab are ongoing. 
Neoadjuvant studies are also ongoing and carry significant promise.
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Background: Multiple mechanisms of melanoma-induced immune 
escape contribute to the failure of the spontaneous or vaccine-
induced immune T cell responses to promote tumor regression in 
humans. In particular, a number of inhibitory pathways play a critical 
role in impeding T cell responses to tumor antigens, including PD-1, 
Tim-3 and TIGIT.
Results: Our findings show that PD-1, Tim-3 and TIGIT are upregu-
lated by CD8+ and CD4+ T cells at the periphery and at tumor sites 
in patients with metastatic melanoma. We observed that melanoma 
cells and antigen presenting cells in metastatic melanoma express the 
PD-1, Tim-3 and TIGIT inhibitory ligands. Dual PD-1/Tim-3 and dual 
PD-1/TIGIT blockades enhanced the expansion and function of TA-
specific CD8+ T cells isolated from patients with advanced melanoma. 
Interestingly, CD8+ TILs downregulated CD226, the costimulatory 
counterpart to TIGIT, supporting an imbalance of TIGIT/CD226 expres-
sion in metastatic melanoma, which may contribute to melanoma-
induced T cell dysfunction.
Conclusion: Collectively, our findings present the rationale for target-
ing multiple inhibitory pathways including PD-1, Tim-3 and TIGIT to 
better counteract melanoma-induced cell dysfunction and improve 
melanoma patients ‘clinical outcome.
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T cells engineered to express high affinity T cell receptors or chimeric 
antigen receptors (CAR) have been successful for treating cancer and 
hematological malignancies. We are using anti-CD19 and anti-CD22 
CAR T cells to treat patients with acute lymphocytic leukemia and B cell 
lymphomas. While early phase clinical studies with these therapies have 
been promising, occasionally, the CAR T cells fail to expand in culture 
resulting in inadequate doses of transduced cells for effective therapy. 
The poor expansion of the T cells appears to be related contamination 
of the autologous leukocyte apheresis products used as starting mate-
rial with large quantities of monocytes or granulocytes. We have been 
evaluating manufacturing methods that make use of lymphocyte 
enrichment prior to initiating the T cell culture. The methods include 
plastic adherence, elutriation and CD4/CD8 cell selection. Another limi-
tation of CAR T cell therapy is their limited in vivo survival. In order to 
improve the in vivo survival and expansion of CAR T cells a GMP method 
has been developed to isolate, transduce and expand stem memory T 
cells (Tscm). CD19 CAR Tscm will soon be tested in a clinical trial which 
will treat adults with B cell malignancies. Limited survival of genetically 
engineered T cells may also be due to immune reactions to the single 
chain variable portion of the mouse monoclonal antibody used in the 
vector. Investigators at our institution have developed a lentiviral vector 
with humanized anti-CD19 for CAR T cell therapy.
Tumor microenvironment and biomarkers
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Background: Exosomes are endosome-derived nanovesicles involved 
in intercellar cross-talk through the transfer of proteins and genetic 
material. Accumulating data suggests that exosomes released from 
tumor cells may play an essential role in modulating host microen-
vironment, conditioning tumor immunity both at local and systemic 
level. We have been collecting evidence that these nanovesicles exert 
a broad array of detrimental effects on the immune system, such as 
impairment of monocyte differentiation into dendritic cells and induc-
tion of suppressive effectors.
Materials and methods: An in vitro model on MDSC conversion from 
normal monocytes by tumor exosomes (Exo-MDSC) was developed and 
used to study the molecular pathways involved in MDSC generation. 
Gene-expression and miRNA profiling of exo-MDSC, blood myeloid cells 
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and plasma exosomes isolated from melanoma patients, and in  vitro 
studies with antagonists and mimics, were applied to identify the miR-
NAs responsible for exosome-MDSC cross-talk in vitro and in vivo.
Results: Compared to untreated monocytes, Exo-MDSC release higher 
levels of protumorigenic and immunosuppressive cyto/chemokines, 
down-modulate the expression of HLA-DR and acquire the ability to 
inhibit T cell proliferation. A gene-expression signature, involving 
CCL2, IL6 and PD1L, and a defined miRNA profiling have been iden-
tified in Exo-MDSC. Using miRNA mimics and inhibitors we demon-
strated a strong impact on the regulation of HLA-DR, IL6 and CCL2 for 
four candidate miRNA, suggesting their involvement in MDSC differ-
entiation. Furthermore, the silencing of these miRNA in melanoma cell 
lines abrogates exosome conversion potential, sustaining the hypoth-
esis of miRNA transfer via exosomes. Importantly, peripheral blood 
monocytes from melanoma patients share defined traits of Exo-MDSC 
gene-expression and miRNA signature, in addition to phenotypic and 
functional features. In addition, extracellular vesicles isolated from 
plasma of melanoma patients, but not from healthy donors, induce 
MDSC conversion ex vivo, and show a higher concentration of myelo-
conditioning miRNA.
Conclusions: Tumor exosomes are involved in triggering MDSC con-
version by directly transferring myelo-active miRNAs to myeloid cells. 
Since MDSC accumulate in peripheral blood of tumor patients in asso-
ciation with disease progression, the identification of exosomes and 
myelo-conditioning miRNA paves the way for the development of 
novel immune-based therapeutic strategies and prognostic biomark-
ers in cancer.
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Advances in cancer immunotherapy, including positive results from 
clinical trials testing new agents and combinations become applicable 
and effective treatment for many common and deadly cancers. How-
ever, a critical limitation in cancer therapy remains the identification 
of patients likely to respond to a given immunotherapy who could 
be stratified for treatment. The Society for Immunotherapy of Can-
cer (SITC) organized workshops and working groups in the past that 
focused on immune prognostic and predictive biomarkers and immu-
nologic monitoring (1–2). SITC Taskforce on Immunotherapy Biomark-
ers developed a series of recommendations and resources for the field 
(3–4).
Although, the field still lacks standardized and validated biomarkers 
to identify the patients who are responding to a treatment specific 
immunotherapies and who will have minimal or acceptable toxicities 
there are, many promising candidate assays, novel technologies and 
molecules. Importantly, companion diagnostic assay for response in 
non-small cell lung cancer have been recently approved by the FDA 
for patients selection for immunotherapy (PD-L1 IHC 22C3 pharmDx).
In light of these developments SITC Immune Biomarkers Taskforce 
has reconvened to review the state of the art, identify current hurdles 
to further success and to make recommendations to the field. Topics 
being addressed by individual working groups include: (1) validation 
of candidate biomarkers, (2) identification of the most promising tech-
nologies, (3) testing of high throughput immune signatures and (4) 
investigation of the pre-treatment tumor microenvironment. Result-
ant recommendations will be published in JITC and discussed during 
the workshop in April 2016.
Specific focus of the talk will be an update from the activity of working 
group 1 (WG1), led by Drs. Magdalena Thurin and Giuseppe Masucci, 
focusing on immunologic assays’ standardization and validation. This 
group includes experts from the US National Cancer Institute (NCI), 
academia, the US FDA, biotech and pharma. They are developing 
roadmaps for standardization and validation of specific assays that 
are currently seen as the most promising, particularly with companion 
diagnostics as the goal. They are also examining proficiency panels of 
assays, and “integral” and “integrated” (versus exploratory) biomarkers 
in clinical trials, and statistical designs for biomarker validation.
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Background: The TNM classification from the UICC/AJCC and the 
guidelines of the WHO 2010 are the basis for the classification of colo-
rectal cancer (CRC). Three clinical scenarios still require novel, reproduc-
ible and standardized biomarkers: malignant polyps, stage II CRC with 
adverse prognosis and the pre-operative management of colon and 
rectal cancer patients. The immunoscore using immune markers CD3 
and CD8 is a promising prognostic approach based on immunohisto-
chemistry and a digital scoring system. Nevertheless, there is still the 
challenge to implement the immunoscore in daily diagnostic practice 
in surgical pathology. The aim of this study is to present the results 
experienced at our Institute of Pathology as one of the participating 
centers.
Materials and methods: The immunoscore (CD3 and CD8) was per-
formed on 331 well characterized CRC patients including the TNM 
classification, L and V stage, perineuronal infiltration, histological sub-
type, tumor grade, peritumoral inflammation, mismatch repair status, 
overall survival and information on adjuvant radio- and chemotherapy 
using the Roche Benchmark II Ultra and the Definiens Software for the 
digital pathology analysis. All the tests were performed at the Transla-
tional Research Unit (TRU) of the Institute of Pathology, University of 
Bern.
Results: The total turn-around time (TAT) for one case is approxi-
mately 15  h including 12  h for immunostaining, 10–20  min for scan-
ning, 30 min for definition of the tumor area and 2 h for calculation. 
These results demand a well defined working process. Therefore, we 
elaborated a possible work flow approach based on the LEAN man-
agement system: phase 1: CRC diagnosis, block selection and digital 
order of CD3 and CD8 by the pathologist; phase 2: immunohistochem-
ical staining and scanning by the immunohistochemistry laboratory; 
phase 3: definition of the tumor area, calculation and reporting of 
the results by the pathologist; phase 4: discussion of the results at the 
interdisciplinary CRC board.
Conclusions: The implementation of the immunoscore in surgical 
pathology on the operative level needs a well defined strategy which 
is simple, applicable and user-friendly. Therefore, based on our experi-
ence well defined working processes based on SOPs and TATs in the 
surgical pathology divisions and digital pathology development units 
which test novel and promising digital scoring systems before the 
implementation in the daily diagnostic practice should be considered.
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We provided evidence that the type, the density and the location of 
immune cells within colonic tumor strongly influence the progno-
sis, independently of the TNM classification [1–4]. Thus, the adaptive 
immune reaction composed of T lymphocytes (CD3) with cytotoxic 
(CD8) and memory (CD45RO) phenotype within the core of the tumor 
(CT) and the invasive margin (IM) is a highly significant parameter to 
predict recurrence and survival. Multivariate analyses have revealed that 
T cell–immune parameters not only remain meaningful when combined 
with the TNM staging system but also were shown to be more accurate 
in determining prognosis than are conventional clinicopathological 
criteria. These data strongly suggests that tumor behavior should now 
be considered as the result of a balance between the invasive tumor 
process and the response of the host of which the local immune reac-
tion is a major component. We established a methodology named 
“Immunoscore” to assess in clinical practice the immune infiltrate. Each 
tumor is categorized into Hi or Lo density for each marker in each tumor 
region, according to a predetermined cut-off value using the minimum 
P value approach. Patients are stratified according to a score ranging 
from I0 to I4 depending on the total number of high densities observed 
(two markers assessed in CT, two markers assessed in IM). For example, 
I4 refers to a tumor with high densities of CD3 and CD8 cells in CT and 
IM regions. We recently applied this classification in patients with clini-
cally localized rectal cancer treated by primary surgery [5] and showed 
that the Immunoscore could be a useful prognostic marker. Cox multi-
variate analysis supports the advantage of the Immunoscore compared 
with the tumor–node–metastasis (TNM) staging in predicting recur-
rence and survival and the lymph node ratio (LNR) added information in 
the prognostic model. The information carried by the LNR could reflect 
complementary aspects of the antitumor immunity not depicted by 
the Immunoscore. In an effort to promote use of the Immunoscore in 
routine clinical settings, an international task force was initiated, sup-
ported by the Society for Immunotherapy of Cancer (SITC) [6]. An inde-
pendent international panel of expert laboratories has started to work 
on large retrospective cohorts of colonic cancers (TNM stage I-III) to 
test the Immunoscore in routine clinical settings. The availability of the 
Immunoscore could significantly improve the prognostic assessment of 
patients and better guide the therapeutic decision, and possibly choos-
ing patients likely to benefit from immunotherapy.
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Background: Each year in Europe, 62,000 new cases of melanoma are 
diagnosed. DTIC was considered the Standard of Care until the appear-
ance of two new classes of compounds in the treatment of metastatic 
melanoma. These drugs were a CTLA-4 blocking antibody and the 
therapies targeting the BRAF kinase pathways. Recently, Nivolumab a 
highly specific programmed death-1 (PD-1) checkpoint inhibitor has 
been authorised [1]. In this oral communication, the regulatory experi-
ence with nivolumab is reviewed.
Materials and methods: European public assessment report (a set 
of documents describing the evaluation of a medicine authorised via 
the centralised procedure) and the publications of the clinical trials of 
nivolumab, will be the basis for the review.
Results: The background for the authorisation of nivolumab in the treat-
ment of subjects with advanced melanoma were two different studies: 
study CA209037 [2, 3]: a phase 3 trial of nivolumab vs investigator’s 
choice in advanced Melanoma patients progressing post anti-CTLA-4 
therapy; and Study CA209069 [2, 4]: a phase 3, study of nivolumab vs 
dacarbazine in subjects with BRAF wild type, previously untreated.
Nivolumab shown convincing statistically significant and clinically rel-
evant results in the first-line treatment of metastatic melanoma. Unfor-
tunately, mature data on OS are not available, since only 34 % of the 
events have occurred. However, it seems reasonable to assume that 
the higher life expectancy associated to nivolumab in first line will be 
maintained.
Regarding the use of nivolumab in last line, after failure of ipilimumab 
and/or BRAF inhibitors, positive results have been observed for ORR 
and PFS although limited to a subset of patients. However, the OS 
curves show an unexpected profile with the lines crossing between 
6 and 9  months. It seems plausible that the delay in the onset of 
the effect of nivolumab (3 months) contributes to the higher rate of 
deaths in the nivolumab arm in the first 3 months of treatment. This 
effect has been also observed in the treatment of non-squamous 
non–small-cell lung cancer (NSCLC) that had progressed during or 
after platinum-based doublet chemotherapy [5]. On the contrary, 
the same molecule has shown a clear benefit in survival in squamous 
NSCLC [6, 7].
Conclusions: The use of nivolumab in some patients might mean a 
worse option than chemotherapy. It remains a challenge to identify 
those patients who could have a chance to benefit from nivolumab.
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Background: Interest in onco immunotherapies has been growing 
in last years, due to market launch of ipilimumab for advanced mela-
noma. Ipilimumab provides important benefits, but is also very costly 
(1, 2). Its incremental cost-effectiveness is over thresholds and closer 
to the 50 k Euro per life-year saved threshold if US list prices (3) and 
European prices (4) are respectively used. NICE recommended ipili-
mumab with a hidden discount on list price. Drugs pipelines include 
many new onco immunotherapy. An assessment framework of their 
value for money is needed for managing their future market access 
(reimbursement/price/recommendation). The present research aims at 
providing some pillars of this framework.
Materials and methods: The study follows a Delphi methodology, a 
technique used to facilitate information-gathering on complex issues (5). 
More specifically, we relied on a e-Delphi (6) organized in three rounds 
and involving nine experts, including clinicians, health economists and 
payers. Panelists were asked to comment on ten statements, explaining 
the extent to which they agreed or disagreed with assertions. Statements 
were subsequently modified and resubmitted for a final consensus.
Results: This paragraph quotes six of the ten statements. The other 
four specifically concern the Italian context. (i) Medium-long term sur-
vival is the most appropriate endpoint to consider for market access 
of onco immunotherapies. Progression Free Survival and Best Overall 
Response Rate do not fully express benefits and immuno-related sur-
rogate endpoints still need surrogacy validation. (ii) More specifically, 
the increase in 2–5 years probability of survival is the most important 
indicator. Quality of life and adverse events should be also considered. 
(iii) Market access would be easier managed if methods requirements 
(endpoints, indicators, follow-up, statistical analysis) are strength-
ened. (iv) Cost-effectiveness used for market access purposes should 
rely on robust extrapolation of future survival; results provided by the 
industry should be validated by independent research groups; incre-
mental cost-effectiveness ratio thresholds should be carefully applied; 
cost-effectiveness should be integrated with a budget impact analy-
sis. (v) Coverage with evidence development agreements should be 
implemented, due to benefits long-term and uncertainty: this requires 
post-approval evidence on survival, quality of life and costs. (vi) Long-
term survival predictive factors would be extremely useful to enhance 
sustainability, provided that they actually reduce uncertainty. Manu-
facturer funded treatment initiation may be applied for expected non-
responders. However clinical research has not found reliable markers 
for onco immunotherapies yet.
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Background: Blocking the immune checkpoint molecule Cytotoxic 
T-lymphocyte antigen-4 (CTLA-4) with ipilimumab has proven to 
induce long-lasting clinical responses in patients with metastatic 
melanoma. Although the theoretic base for the success of this therapy 
has been described, the detailed mechanisms involved are not yet 
fully understood. In addition to this, there is a great need of predic-
tive, prognostic and pharmacodynamic biomarkers that may allow 
clinicians to screen for immune related adverse events and potentially 
provide information for patient preselection. In this study we show the 
results derived from the immune monitoring of advanced melanoma 
patients undergoing treatment with ipilimumab.
Materials and methods: Peripheral blood mononuclear cells (PBMCs) 
were isolated from 42 melanoma patients at three time points before 
and during treatment. PBMCs were stained with 12 multi-color flow 
cytometric panels within 2 h of sample collection.
Results: The results show that ipilimumab treatment contributes to 
activate CD 4 T cells as is shown by a significant increase in the fre-
quency of ICOS + CD4 cells. This increase is correlated with a decrease 
in the frequency of granulocytic MDSCs (grMDSCs) and their suppres-
sive potential, determined by their intracellular Arg1 levels. In con-
trast to these results, monocytic MDSC (moMDSC) frequency was not 
affected by CTLA-4 blockade, but the frequency of iNOS + cells within 
this MDSC subset was diminished. This suggests that that at least one 
of the suppressive mechanisms used by moMDSCs is impaired. Regu-
latory T cells (Tregs) were also reduced, although their pattern did not 
correlate with MDSC or activated T cell frequency.
In the 42 patients included, median OS was 55 weeks from the start of 
treatment. Adverse events were observed in 16 patients (38 %), includ-
ing eight grade III–IV (19 %). Patients were classified according to their 
response as PD (progressive disease, 57 %), SD (stable disease, 23 %) 
and PR (partial response, 20  %). Possible correlations between treat-
ment outcome and MDSC frequencies are currently being evaluated as 
the patient cohort increases.
Conclusions: These results suggest that there may be more than 
one mechanism of action by which ipilimumab releases the brake 
on the immune system. On one hand, blocking CTLA-4 results in an 
in cis effect on the activation status of CD4+ T cells. On the other 
hand the observed reduction in Tregs and MDSCs (in frequency and 
suppressive potential) may contribute to significantly alleviate the 
suppression exerted on the immune system. These effects and their 
possible clinical implications should be further explored in order to 
fully understand the mechanisms of action of CTLA-4 blockade with 
ipilimumab.
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Background: Melanoma is a malignant tumor highly immuno-modu-
lated, therefore different immunotherapy approaches in recent years 
have been developed. In addition, the American Society of Clinical 
Oncology (ASCO) Annual Meeting 2015 has emphasized the use of 
combined treatment strategies involving immunotherapies and/or 
biological agents target [1].
PD-L1 (programmed cell death ligand 1) is a membrane receptor that 
plays a key role in the suppression of immune responses, mainly by 
binding to PD-1 on T lymphocytes. PD-L1 can be expressed in meta-
static melanoma and may be an independent prognostic marker in 
melanoma [2, 3]. Currently, target therapies against both PD-L1 and 
PD-1 are adopt in clinical trial. COX-2 is an enzyme that catalyzes the 
conversion of arachidonic acid to prostaglandins and active throm-
boxanes. Their activity occurs in the sites in which is present an inflam-
matory state. FANS can cause blocking of their biosynthesis. Several 
studies in the literature have shown aberrant expression of COX-2 in 
melanoma, especially in advanced stages [4].
The purpose of this study was to analyze the expression of COX-2 and 
PD-L1 in a series of primary melanomas and lymph node metastases in 
order to establish their prognostic value and provide information on 
the possibility of adopting combined therapeutic strategies.
Materials and methods: We have prepared a Tissue Micro Array con-
taining 90 samples, consisting of 45 primary and 45 lymph node metas-
tases from melanoma. On the sections of TMA the expression of COX-2 
and PD-L1 (clone 5H1) was evaluated by immunohistochemical staining.
Results: Immunohistochemical analysis performed on samples of pri-
mary melanomas revealed that 20/45 (44.4) cases were positive for 
PDL1 and 16/45 (35.5  %) for COX2; for lymph node metastasis 23/45 
(51.1 %) cases were positive for PDL1 and 19/45 (42.2 %) cases for COX2.
Our results demonstrated that the expression of COX-2 and PD-L1 
were directly related both with primary tumors (p value = 0.003) and 
with the lymph node metastasis (p value  =  0.002) of melanoma. In 
particular COX2 and PDL1 co-expression in primary melanomas was 
present in 12/45 cases (26.6 %) while it was absent in 21/45 (46.7 %) 
cases.
Instead the expression of COX2 and PDL1 in the lymph node metas-
tases were present in 18/45 cases (40  %) while it is absent in 15/45 
(33.3 %) cases.
Conclusions: The combined expression of both markers either in pri-
mary tumors than in lymph node metastases from melanoma could 
suggest new therapeutic strategies in the modulation of PD-L1 and 
COX-2 inhibitors.
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Background: The BRIM-3 trial showed improved progression-free sur-
vival (PFS) and overall survival (OS) for vemurafenib compared with 
dacarbazine in drug-naive BRAFV600 mutation–positive metastatic mel-
anoma patients. Vemurafenib has shown a 74 % reduction in the risk 
for death or disease progression and a 63 % reduction in the risk for 
death compared with dacarbazine (P < 0.001 for both comparisons).
Materials and methods: Patients were randomly assigned to receive 
vemurafenib (960 mg BID) or dacarbazine (1000 mg/m2 every 3 week). 
OS and PFS were coprimary end points. OS was assessed in the inten-
tion-to-treat population, with and without censoring of data for dac-
arbazine patients who crossed over to vemurafenib. Effects of age, 
disease stage, baseline lactate dehydrogenase value, baseline Eastern 
Cooperative Oncology Group performance status (ECOG PS) value, 
and prior therapies were also analyzed by treatment received.
Results: A total of 675 patients were randomly assigned to receive vemu-
rafenib (n = 337) or dacarbazine (n = 338). At the time of database lock 
(Aug 14, 2015), median follow-up was 13.37  months (range 0.4–59.6) 
for vemurafenib and 9.15 months (range 0–56.2) for dacarbazine. Of 338 
patients initially randomly assigned to receive dacarbazine, 84 crossed over 
to vemurafenib. Subgroup analyses and final OS data will be presented.
Conclusions: Extended follow-up of patients enrolled in BRIM-3 pro-
vides insight regarding long-term efficacy and safety of vemurafenib 
in patients with metastatic melanoma and BRAFV600 mutations.
Clinical trial registration number: NCT01006980.
Acknowledgement: Supported by F. Hoffman-La Roche Ltd.
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Background: The phase 3 study CheckMate 067 (NCT01844505) 
showed improved progression-free survival (PFS) and objective 
response rate (ORR) by RECIST v1.1 for NIVO (anti-PD-1)  +  IPI (anti-
CTLA-4) (median 11.5 months [mo], 58 %) or NIVO (6.9 months, 44 %) 
compared with IPI (2.9 months, 19 %) in patients (pts) with previously 
untreated advanced melanoma [1]; however, long-term follow-up data 
including overall survival (OS) are not yet available. Updated data from 
CA209-004 (NCT01024231) in pts with unresectable or metastatic mel-
anoma are reported here.
Materials and methods: Cohorts [C] 1, 2, 2a, and 3 received NIVO + IPI 
Q3W × 4 followed by NIVO Q3W × 4; pts without progressive disease 
or dose-limiting toxicity received NIVO + IPI Q12W × 8. An expansion 
cohort (C8) received NIVO 1 mg/kg +  IPI 3 mg/kg Q3W × 4 followed 
by NIVO 3  mg/kg Q2W (regimen used in phase 2/3 trials). Data are 
reported for C1-3 (n = 53) and C8 (n = 41).
Results: 40  % of pts in C1-3 and 51  % of pts in C8 were previously 
treated. At a median follow-up of 32.7  months (range: 2.5–61.4) for 
C1-3 and 19.9 months (range: 0.9–24.0) for C8, ORR by mWHO criteria 
was 42 and 44 %, respectively, and the median duration of response 
was 22.3 and 13.8 months. Complete response was seen in 21 % of pts 
in C1-3 and 17 % of pts in C8, and the median tumor burden reduc-
tion was 70 and 58 %, respectively. OS rates were 79 % at 24 months in 
C1-3 and 68 % at 18 months in C8. PFS rates were 30 % at 24 months in 
C1-3 and 27 % at 18 months in C8. Incidence of drug-related adverse 
events (AEs) was 56 % for grade 3/4 AEs and 39 % for grade 3/4 select 
AEs in C1-3 and C8 combined (n = 94).
Conclusions: OS for concurrent NIVO + IPI was higher than expected for 
each agent alone in this population, with a manageable safety profile.
Reused with permission from the Society for Melanoma Research 
(SMR) and all authors.
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Background: The primary analysis of coBRIM showed superior pro-
gression-free survival (PFS) for COBI + VEM in advanced BRAF-mutated 
melanoma pts [1]. We present the protocol-defined, updated PFS 
analysis and final OS analysis and correlate these efficacy results to key 
biomarkers.
Materials and methods: coBRIM has been described previously [1]. 
Pts were randomly assigned to receive COBI  +  VEM or PBO  +  VEM. 
Primary endpoint was investigator-assessed PFS; overall survival (OS) 
was a secondary endpoint. Following the primary PFS analysis, coBRIM 
remained blinded, and pts were followed up for OS. Final OS analysis 
occurred after 250 events. For biomarker analysis, pretreatment tumor 
samples were evaluated for BRAFV600 allele frequency (BRAFV600 copy 
number) by targeted deep sequencing and pathway activation by 
pERK, pS6, and PTEN, and Ki67 by immunohistochemistry. Cox propor-
tional hazards models were used to assess the association between OS 
and biomarkers.
Results: From Jan 2014 to Jan 2015, 495 pts were randomly assigned. 
Baseline characteristics in COBI + VEM and PBO + VEM pts were East-
ern Cooperative Oncology Group (ECOG) 0: 76 and 67 %; stage IV M1c: 
59 and 62 %; LDH high: 46 and 43 %. Updated PFS analysis was con-
ducted after a median follow-up of 14.3 months and showed a median 
PFS of 12.3  months for COBI  +  VEM vs 7.2  months for PBO  +  VEM 
(HR, 0.58; 95 % CI; 0.46–0.72). PFS treatment benefit was seen across 
all prespecified patient subgroups, including patients with LDH high 
(COBI + VEM 8.2  months vs PBO + VEM 5.4  months; HR, 0.57; 95  % 
CI, 0.42–0.78) and normal (COBI +  VEM 13.4  months vs PBO +  VEM 
7.8 months; HR, 0.59; 95 % CI, 0.43–0.81).
Final OS analysis was conducted after a median follow-up of 
18.5  months and confirmed a statistically significant and clinically 
meaningful benefit for pts receiving COBI + VEM. OS data and correla-
tion of key biomarkers with OS and PFS will be presented.
Conclusions: Updated PFS and OS data confirm the clinical benefit of 
COBI + VEM across all clinical and molecular subgroups vs PBO + VEM 
in patients with advanced BRAF-mutated melanoma.
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Background: BRAF-targeted therapy with vemurafenib (V) is associ-
ated with increased immune activation in BRAFV600-mutant melanoma, 
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resulting in a rapid clinical response. The durability of response can 
potentially be further extended by combining V and atezolizumab (A; 
MPDL3280A), which may enhance and perpetuate antitumor immune 
activity.
Materials and methods: Patients with untreated BRAFV600-mutant 
unresectable or metastatic melanoma received A  +  V combination 
concurrently (cohort 1 [C1], n = 3) or after a run-in period with V alone 
(56  days for cohort 2 [C2, n  =  8]; 28  days for cohort 3 [C3, n  =  6]). 
Administration of A was IV q3w at 20  mg/kg (C1) and 15  mg/kg or 
1200 mg fixed (C2 and C3). V was administered orally BID 960 mg dur-
ing run-in and 720  mg during the A + V combination period. PD-L1 
expression on tumor cells and tumor-infiltrating immune cells was 
centrally examined by immunohistochemistry (SP142 assay).
Results: Of 19 BRAF inhibitor—and immunotherapy-naive patients 
enrolled, 17 who received ≥1 dose of A were safety and efficacy 
evaluable (data cutoff, Mar 16, 2015). Across cohorts, 65 % of patients 
were male and median age was 53 y (range, 30–71 y). Patients 
received A + V combination for a median of 8.5 months (range, 1.2–
27.8  months). Median safety follow-up (mo) was 6.5 (C1), 10.6 (C2) 
and 10.4 (C3). A + V did not result in any DLTs or unexpected AEs. Inci-
dence of A- or V-related G3 AEs was 41 and 59 %, respectively, and was 
higher in C1 (67 % A; 100 % V) than in C2 (38 % A; 50 % V) or C3 (33 % 
A; 50 % V). AEs were manageable and generally reversible. Related G4 
AEs were absent. No G5 AEs occurred. There were no A-related AEs 
leading to treatment discontinuation; 1 patient in C1 had V-related 
AEs leading to discontinuation. Clinical activity results are presented 
in Table  1. Higher ORR was seen with V run-in (C2, 75  %; C3, 100  %) 
than with concurrent A + V start (C1, 33 %). Preliminary data indicate 
an increase in PD-L1 expression in repeat biopsies after V run-in or 
A + V combination, suggesting induction of an enhanced antitumor 
immune response.
Conclusions: Overall, a manageable safety profile and promising anti-
tumor activity were demonstrated with A + V combination therapy. 
In particular, staggered dosing of A with V run-in was better tolerated 
and yielded high rates of durable response. Triple-combination ther-
apy with A + V+cobimetinib (MEK inhibitor) in this patient population 
is under investigation. (NCT01656642).
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Background: Indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan-
catabolizing enzyme that induces immune tolerance by suppressing 
T-cell responses. Epacadostat is a potent, selective oral IDO1 inhibitor. 
In a dose-escalation study in patients with metastatic melanoma, the 
combination of epacadostat with ipilimumab was generally tolerated 
and favorable response rates were observed in immunotherapy-naive 
patients.
Materials and methods: NCT02178722 is an ongoing study of epaca-
dostat with pembrolizumab in patients with advanced melanoma 
and other cancers with a 3 + 3+ 3 phase 1 design. Patients previously 
treated with checkpoint inhibitors were excluded. During dose-esca-
lation, patients received epacadostat 25, 50, or 100 mg BID with pem-
brolizumab 2 mg/kg IV every 3 weeks or epacadostat 300 mg BID with 
pembrolizumab 200  mg IV every 3  weeks. During dose-expansion, 
patients received epacadostat 50, 100, or 300 mg BID with pembroli-
zumab 200 mg IV every 3 weeks. Safety, tolerability, and investigator-
assessed tumor response (RECIST 1.1) were evaluated.
Results: As of 29 Oct 2015, 62 patients were enrolled. Safety data 
on 56 patients with either melanoma (n = 20), RCC (n = 11), NSCLC 
(n = 10), transitional cell carcinoma (n = 5), endometrial adenocar-
cinoma (n = 5), TNBC (n = 3), or SCCHN (n = 2) as of October 1, 2015 
are presented. The most common all grade treatment-related AEs 
were rash (25  %), fatigue (23  %), arthralgia (13  %), pruritus (13  %), 
nausea (11  %), and pyrexia (11  %). Grade 3 treatment-related AEs 
occurred in 11 % of patients; the most common grade 3 treatment-
related AE was rash (5 %). There were no grade 4 treatment-related 
AEs and no treatment-related deaths. One patient discontinued for 
a treatment-related AE (grade 3 AST elevation). In 19 efficacy evalu-
able melanoma patients, ORR was 53 % and disease control rate was 
74 % (3 CRs, 7 PRs, 4 SDs). Responses occurred in patients who were 
PD-L1-positive and PD-L1-negative (PD-L1 IHC 22C3 pharmDx Kit; 
≥1 % cutoff for positivity). All responses are ongoing as of the data 
cutoff.
Conclusion: Preliminary safety data support continued evaluation of 
epacadostat with pembrolizumab. Although preliminary, the efficacy 
data suggest promising clinical activity of the combination in patients 
with advanced/metastatic melanoma. Updated safety data will be 
presented.
Table 1 Clinical activity results
Cohort 1  
(n = 3)
Cohort 2  
(n = 8)




Objective response (confirmed, RECIST v1.1)
 ORR,  % (n) 33 % (1) 75 % (6) 100 % (6) 76 % (13)
 CR,  % (n) 33 % (1) 12 % (1) 17 % (1) 18 % (3)
 PR,  % (n) 0 62 % (5) 83 % (5) 59 % (10)
PFS
 Median, mo 
(95 % CI)
2.7 (1.7, 22.0) 12.2 (4.6, NE) NE (NE) 12.2 (5.7–22.0)
DOR
 Median, mo 
(95 % CI)
20.9 (NE) 10.6 (4.9, NE) NE (NE) 20.9 (10.6, 20.9)
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Background: T-VEC is a herpes simplex virus-1 -based oncolytic 
immunotherapy designed to selectively replicate in tumors, pro-
duce GM-CSF, and stimulate antitumor immune responses. T-VEC 
significantly improved durable response rate (DRR; primary end-
point) in the T-VEC arm vs GM-CSF in OPTiM (Andtbacka et  al. JCO 
2015) and is approved in the US for local treatment of unresect-
able cutaneous, subcutaneous, and nodal lesions in patients with 
melanoma recurrent after initial surgery. Pembro is a PD-1 block-
ing antibody approved for the treatment of advanced metastatic 
or unresectable melanoma and has demonstrated superiority over 
the CTLA-4-blocking antibody ipilimumab in patients with stage III 
or IV melanoma (Robert et  al. NEJM 2015). Both drugs have toler-
able and non-overlapping adverse event (AE) profiles, and combin-
ing them may enhance antitumor efficacy. Safety and preliminary 
efficacy data from the phase 1b primary analysis of a phase 1b/3 
study of T-VEC  +  pembro in unresectable stage IIIB-IV melanoma 
(NCT02263508) are reported.
Materials and methods: The primary endpoint is incidence of dose-
limiting toxicities (DLT). Key secondary endpoints are objective 
response, survival, and AEs. Patients had stage IIIB-IV melanoma with 
injectable lesions, no prior systemic therapy, and ECOG PS 0-1. T-VEC 
was given ≤4 mL injected into (sub)cutaneous/nodal lesions 106 PFU/
mL d1, 108 PFU/mL d22 then Q2W. Pembro was given IV 200 mg d36 
then Q2W. Treatment (tx) continues until.
CR, all injectable tumors have disappeared (for T-VEC), confirmed PD 
per modified immune-related response criteria, intolerance of study 
treatment, 24 months from the date of the first dose of pembro or end 
of study, whichever occurs first.
Results: 21 patients were enrolled Dec 2014-Mar 2015 with data cut-
off of Jun 2015. Patient characteristics: median age 58 year; 48 % stage 
IIIB-IVM1a, 52 % stage IVM1b/c melanoma; 81 % PD-L1+; 76 % HSV+. 
Median follow-up time was 18.7 w. No DLTs were reported. All 21 
patients had an AE: 29 % G3, no G4, and one G5 (not attributed to tx). 
Most common AEs were fatigue 52 %, pyrexia 48 %, chills 43 %, and 
rash 38 %. Of 16 patients ≥12 w after first pembro tx and with evalu-
able response assessment, unconfirmed response rate per investigator 
was 56 %; disease control rate was 69 % (12.5 % CR, 44 % PR, 12.5 % 
SD, 31 % PD).
Conclusions: T-VEC+ pembro can be given at full doses with no 
unexpected safety signals. Responses were seen in over half of eval-
uable patients in this early efficacy analysis. A randomized phase 
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Background: In a phase 3, randomized study (CheckMate 066, 
NCT01721772), NIVO demonstrated increased overall survival (OS) vs 
DTIC in treatment-naïve BRAF wild-type pts with MEL, and a safety 
profile consistent with prior reports [1]. Here, we report two-year OS as 
well as updated efficacy and safety data.
Materials and methods: 418 treatment-naïve BRAF wild-type pts with 
MEL were randomly assigned to receive NIVO (3 mg/kg Q2W and DTIC-
matched placebo Q3W) or DTIC (1000 mg/m2 Q3W and NIVO-matched 
placebo Q2W).
Results: At a minimum survival follow-up of 15.1 months, NIVO con-
tinued to demonstrate significantly improved OS with median OS 
(mOS) not reached (NR) (95 % CI: 23.1, NR) vs 11.2 months (95 % CI: 9.6, 
13.0) with DTIC (hazard ratio [HR]: 0.43 [95 % CI: 0.33, 0.57; P < 0.0001]). 
OS rates were 70.7 and 57.7 % for NIVO and 46.3 and 26.7 % for DTIC 
at 12 and 24 months, respectively. Subsequent treatment was used in 
48.1 and 72.1 % of pts on NIVO and DTIC, respectively, and 27 DTIC pts 
crossed over to receive NIVO. Median progression-free survival con-
tinued to be significantly greater with NIVO vs DTIC (5.4 vs 2.2 months 
[HR: 0.42 (95  % CI: 0.32, 0.53; P  <  0.0001)]). Objective response rate 
(ORR) remained higher for NIVO (42.9 %) vs DTIC (14.4 %; P < 0.0001). 
A higher rate of complete responses was reported with NIVO (10.5 %) 
vs DTIC (1.0  %); median duration of response was NR vs 7.2  months, 
respectively. Of 90 responders with NIVO, 64 (71  %) had ongoing 
responses vs 4/30 (13 %) with DTIC. Drug-related adverse events (AE) 
were reported in 77 and 78  % of pts on NIVO vs DTIC (drug-related 
grade 3–4 AEs in 13 and 17  %), respectively. Drug-related AEs (any 
grade) led to discontinuation in 6  % of NIVO and 3  % of DTIC pts. 
Among 57 pts who started ipilimumab (IPI) after NIVO, mOS was 
9.0  months (95  % CI: 7.1, 14.7) and ORR was 8.8  % (n =  5, all partial 
responses) after start of IPI. Drug-related AEs were reported in 77 % of 
pts who switched to IPI.
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Conclusions: In summary, NIVO provided durable responses and 
mOS NR with continued acceptable safety after 2  years in pts with 
MEL.
Reused with permission from the Society for Melanoma Research 
(SMR) and all authors.
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Background: Responses to immune checkpoint inhibitors may be 
delayed or may develop after RECIST-defined disease progression [1, 2].
Materials and methods: We conducted a retrospective analysis to 
measure efficacy and safety outcomes in pts treated with NIVO (anti-
PD-1 therapy) beyond RECIST-defined disease progression. Data were 
pooled from treatment-naive MEL pts who received NIVO monother-
apy in phase 3 studies CheckMate 066 (NCT01721772) and CheckMate 
067 (NCT01844505). Progression was assessed by RECIST v1.1 and 
investigators determined which pts might benefit from treatment 
beyond progression.
Results: Of all randomized pts (N  =  526), 298 (57  %) experienced 
RECIST-defined disease progression with NIVO monotherapy. Of these 
298 pts, 158 (53 %) did not continue NIVO treatment (Non-TBP group) 
and 140 (47  %) were treated with at least 1 dose of NIVO beyond 
progression (TBP group). 31/140 (22 %) pts in the TBP group showed 
greater than 30  % reduction in tumor burden after progression in 
comparison with baseline data (TBP30, a subset of the TBP group). 
Median time between progression and last dose of study treatment 
was 6.7 and 36.1 weeks for TBP and TBP30 groups, respectively. Maxi-
mum change in median tumor burden between randomization and 
first progression was an increase of 5.4 % in the TBP group, an increase 
of 20.2 % in the Non-TBP group and a reduction of 45.2 % in the TBP30 
group. Treatment-related grade 3/4 adverse events (AEs) occurred in 
7.0 and 11.4 % of pts in Non-TBP and TBP groups, respectively. Treat-
ment-related select grade 3/4 AEs occurred in 3.8 and 4.3 % of pts in 
Non-TBP and TBP groups, respectively. Additional descriptive data in 
Non-TBP and TBP groups at baseline, during treatment and at progres-
sion will be presented.
Conclusions: These results suggest that pts with RECIST-defined dis-
ease progression can safely continue NIVO treatment and that a pro-
portion of these pts may experience prolonged clinical benefit.
Reused with permission from the Society for Melanoma Research 
(SMR) and all authors.
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Background: About 50  % of metastatic melanomas (MM) harbour 
mutations in the BRAF gene, mainly at codon 600, resulting in con-
stitutive activation of the MAPK pathway [1]. The selective inhibi-
tors of BRAF V600, vemurafenib and dabrafenib have shown major 
tumor responses in about 50 % of patients. However, the majority of 
patients progress after 6–8  months due to several resistance mecha-
nisms which are only partially understood. As both targeting agents 
appear to benefit only certain subsets of patients, the identification 
of predictors of response is mandatory. One of the available strategies 
that facilitates the simultaneous analysis of a large number of factors 
in biological material is surface enhanced laser desorption ionization 
time of flight mass spectrometry (SELDI ToF MS). The purpose of the 
present study is to verify if this high-throughput technique is able to 
individuate novel candidate peptides useful as biomarkers to predict 
the response or resistance to BRAF inhibitors. Moreover, we integrated 
results of our recent study [2] regarding the relationship between 
microRNA expression and response to Vemurafenib in order to better 
understand biological mechanism influencing disease progression.
Materials and methods: In order to discover novel candidate bio-
markers predictive to treatment, serum of 39 MM vemurafenib treated 
patients at baseline, at disease control and at progression, were ana-
lyzed using SELDI-TOF technology. The Mascot Peptide Mass Finger-
print online tool (http://www.matrixscience.com/cgi/search_form.
pl?FORMVER52&SEARCH5PMF) was used to identify more significant 
peaks and miRWalk (http://zmf.umm.uni-heidelberg.de/apps/zmf/mir-
walk2/index.html) to verify interaction between microRNA and genes 
coding for the predicted proteins.
Results: At baseline as predictive biomarkers we identified four 
peaks—m/z 5900, 12544, 49124 and 11724—significantly up-regulated 
in longer versus shorter responders to vemurafenib. After response, 
three peptides m/z 9292, 7765 and 9176 appeared up-regulated in 
responder patients. In silico predictions indicated that the metastatic 
suppressor gene KLF17 and two cellular proteins, RBM10 and TOX3, 
which are involved in proliferation and apoptosis of cancer cells, could 
be the actors influencing the outcome of BRAF inhibitor therapy. TOX3, 
RMB10 and KLF17 resulted target of miR-132-3P, the miRNA whose 
lower expression is associated to shorter progression free survival.
Conclusions: In conclusion, our results highlighted the possibility to 
better stratify patients that could be addressed to BRAF inhibitor ther-
apy. Moreover, the combined analysis of epigenetic, microRNAs, and 
proteomic data could help to uncover the biological mechanism of 
resistance in MM.
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Background: The prognosis of a variety of human malignancies including 
melanoma is dictated by the abundance, spatial trafficking and quality of 
intratumoral T cell infiltrates [1]. Salerno and al. recently studied chemokine 
receptors (CC/CXCR) expression on Tumor-Infiltrating T cells (TILs) from 
several metastasis localizations and suggest a limited tissue-specific hom-
ing to human melanoma [2]. We studied the expression of these CC/CXCR 
on peripheral T cells from metastatic melanoma (MM) patients, during Ipili-
mumab therapy and healthy volunteers (HV). We found an orchestrated 
deregulation of these molecules according to the various sites of disease 
dissemination. Moreover, we discovered some putative biomarkers of 
response to Ipilimumab before and during the therapy such as the amount 
of CD4 and CD8 + CLA + effector memory T cells.
Materials and methods: We assessed this chemokine receptors pro-
filing on 57 cryopreserved blood samples from stage III/IV melanoma 
patients and on 26 HV. Moreover, 47 patients treated with Ipilimumab 
and enrolled in four clinical centers (France, Germany, Italy and USA) 
were studied. We performed flow cytometric analysis of CD4 and CD8 
T cells subsets based on their expression of CCR7 and CD45RA and 
then assessed, for each subset, the expression of CLA, CXCR5, CRTH2, 
CCR10, CD103, CCR9, CXCR4, CXCR3 and CCR6.
Results: Firstly, correlation matrices indicated similar chemokine recep-
tor expression on CD4 and CD8 T cells, except for CXCR4 and CD103, and 
concordant patterns in naïve, effector and memory T cells. After classifi-
cation of patients based on their metastasis localizations with skin and 
lymph node, lung or other distant organs with or without lung involve-
ment, 62 parameters were found to differ significantly (FDR < 0.1) accord-
ing to distinct localizations metastasis. Expression level normalized with 
respect to HV indicated that specific signatures could identify prefer-
ential metastasis localizations. Loss of CCR6 or CXCR3 (but not CLA) on 
circulating T cell subsets was associated with skin or lymph node metas-
tases, loss of CXCR4, CXCR5 and CCR9 with lung involvement, and a raise 
in CCR10 or CD103 with widespread dissemination. High frequencies of 
CD8+CCR9+ TN correlated with prolonged OS (p < 10−4), while neutral-
izing the CCR9/CCL25 axis in mice stimulated tumor progression. Effector 
memory CD4+ and CD8+ expressing CLA increased upon CTLA4 block-
ade, both predicting disease control at 3 months of therapy in 47 MM.
Conclusion: We discovered an immune chemokine receptor profile 
which mirrors the metastatic pattern of the disease and highlighted 
new pharmacodynamic parameters during immune checkpoint block-
ade with Ipilimumab.
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Background: Although Ipilimumab (IPI) definitely improves the PFS 
and extends the OS in metastatic melanoma [1], the immunologic cri-
teria for both evaluation and prediction of the therapeutic response 
are presently uncertain in clinical management of patients. Recently, 
both melanoma [2] and immune cells [3] have been described to 
release exosomes (Exo), namely endomysial microvesicles with anti-
genic and molecular features resembling the original phenotype pat-
tern of the producing cell [4]. Thus, serum levels of Exo may indirectly 
reflect the response to IPI immunotherapy and detection of both CD28 
and PD1 expressed by T cell-released Exo in sera of IPI-treated patients 
may identify the responders, suggesting Exo measurement as a poten-
tial tool to evaluate the immune response against melanoma.
Materials and methods: Sixty patients with advanced melanoma in 
treatment with IPI were enrolled. Sera were collected both before and 
after the four-month treatment, and Exo were purified by the “Total 
Exosome Isolation kit” (Invitrogen, Carlsbad, California). Thus, they were 
investigated by flow-cytometry in their expression of PD1, CD28, ICOS by 
gating the CD3+ cells and CD86 with the purpose to identify Exo released 
by dendritic cells (DEX). Therefore, median levels of PD1-, CD28- and 
ICOS-positive Exo were calculated both at baseline and longitudinally 
and compared with the therapeutic response by waterfall chart. Finally, 
both PFS and OS were calculated by Kaplan–Meier regression analyses.
Results: The therapeutic response to IPI as disease stability, partial 
or complete response, associated with PFS improvement and favour-
able trend of OS, was detected in 12 patients. Data from Exo investi-
gation revealed higher expression of both PD1 and CD28 before IPI 
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(p = 0.03; and 0.008 respectively), whereas the ICOS level expression 
remained mostly unchanged. By contrast, the major group of patients 
with disease progression showed minimal levels of either PD1-, or 
CD28-positive Exo. Interestingly, we found in IPI-responsive patients a 
quantitative increase of DEX after completion of the immunotherapy 
treatment (p < 0.01). Thus, we interpreted this finding as effect of the 
anti-melanoma immune activation.
Conclusions: Our data suggest that higher levels of PD1- and CD28-
positive Exo in sera of melanoma patients before undergoing IPI treat-
ment may predict the anti-melanoma immune activation induced by 
IPI and that the measurement of these molecular biomarkers could 
early identify the melanoma patients responsive to immunotherapy.
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Background: Stage III melanomas (MM) require adequate adjuvant 
immunotherapy to prevent relapses. The magnitude of metastatic 
lymph node (mLN) invasion and a BRAFV600 activating mutation have 
a clinical significance; however, prognostic factors are awaited to opti-
mize the clinical management of these patients.
Materials and methods: We performed a comprehensive immu-
nophenotyping of 252 parameters/patient by flow cytometry and 
ELISA techniques, in paired blood and mLN performed in 39 meta-
static melanomas. Wilcoxon signed-rank test was applied to assess dif-
ferences in concentration between matching pairs of blood leukocytes 
and tumor infiltrated cells samples. Overall Survival (OS) and Relapse 
Free Survival (RFS) determined from the date of sampling were used 
as the primary end-points. Survival curves were estimated by the 
Kaplan–Meier product-limit method.
Results: We found immunotypes corresponding to clinical pres-
entations. mLN extensive invasion was associated with lower lev-
els of circulating CD4+ T cells and lower expressions of CD137L on 
CD3−CD56− cells and PD1 on CD8+, in blood and TILs, respectively. 
BRAF mutation was associated with higher levels of CD45RA+ CD4+ TILs 
and lower expression of CD137L on circulating CD8+ and NK cells. High 
frequencies of tumoral CD45RA+CD4+ and CD3−CD56− TILs were inde-
pendent prognostic factors of short RFS, and remained significant after 
adjusting for mLN invasion, therefore adding prognostic value to local 
aggressiveness. The best predictive markers of OS after adjusting for sig-
nificant clinical variables included NKG2D expression levels on intratu-
moral CTLs, intratumoral Tregs infiltration, and PD-L1 intensity on blood 
T cells. When combined with BRAF mutation, very high percentages of 
NKG2D+CD8+ TILs or low percentages of Tregs protected against the 
BRAF mutation-associated dismal prognosis. In blood, high expression 
levels of PD-L1 on CD4+ and CD8+ T lymphocytes were associated with 
a bad prognosis, also adding value to the BRAF mutational status.
Conclusions: Overall, when classifying our 252 immunological mark-
ers determined in blood and tumor beds according to their biological 
and clinical significance in stage III MM, we concluded that (i) both 
blood and tumor markers equally contributed to defining the progno-
sis, (ii) exhaustion markers markedly affected the clinical outcome and 
(iii) activation markers appeared less relevant for the functional study 
of tumor beds. Only six markers were found to be significant prognos-
tic factors influencing RFS or OS in blood or tumor beds independently 
of clinicopathological parameters in multivariate Cox regression analy-
ses. These immunotypes deserve to be followed in the course of the 
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Background: Combined B-RAF and MEK inhibition elicits rapid anti-
tumor responses in the most patients with B-RAF (V600E) mutant 
metastatic melanoma. However, the vast majority of patients develop 
resistance to these agents [1]. Defining the phenotypic properties of 
Page 15 of 27  J Transl Med 2016, 14(Suppl 1):S65
melanoma cells resistant to single B-RAF and combined with MEK inhi-
bition is critical for therapeutic exploitation.
Materials and methods: Melanoma cell lines, resistant to B-RAF inhib-
itors (B-RAFi) as single agent or combined with MEK inhibitors (MEKi), 
were selected by growing them in medium containing increased 
concentrations of B-RAF inhibitors (B-RAFi: GSK2118436) alone or 
combined MEK inhibitors (MEKi: GSK1120212). Morphological and 
phenotypic investigation was performed by light microscopy, immu-
nofluorescence and flow cytometer analysis.
Results: Here, we detected a cell subset inside of three different mela-
noma cell lines, deriving from patients with B-RAF (V600E) mutant met-
astatic melanoma. This cell-subset was able to proliferate and forming 
colonies at low density in presence of single B-RAF inhibitors (B-RAFi) or 
combined with MEK inhibitors (MEKi), suggesting that drug treatment 
was unable to kill all the cells, but few of them continued to grow form-
ing sizeable colonies as the ones observed from untreated cells.
We enriched this cell-subset, by growing them in drugs and we charac-
terized them by measuring drug IC50 and examining the effect of the 
drug on the cell cycle, by flow cytometer.
Successively, we investigated their morphological and phenotypic 
properties. We found that melanoma cells, resistant to B-RAFi alone or 
combined with MEKi, exhibited a bigger cellular body, an increased 
inter-cellular space and the pseudopodia formation compared to their 
sensitive counterparts. FACS analysis of CD90 and CD324 markers 
revealed an increased expression of CD90 with a reduction of CD324 
in resistant cells. In addition, the drug resistant cells were able to attach 
and spread on the plate, in a 3D culture system, while the sensitive ones 
were unable to do it. We also found a reorganization of the network of 
vimentin mainly localized at perinuclear sites in the drug resistant cells. 
All together these data supported a mesenchymal-like phenotype of 
the melanoma cells, resistant to B-RAFi alone or combined with MEKi.
Conclusions: These data suggest that melanoma cells contained a 
cell-subset with mesenchymal-like features that were resistant to 
B-RAFi and MEKi drugs [2]. Further characterization of these cells will 
help to define novel targets opening up the possibility to develop effi-
cacious therapeutic strategies and contributing to overcome the big 
issue of drug resistance in melanoma.
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Background: Despite novel therapeutic treatments developed in 
recent years, advanced melanoma patients continue to die. Therefore, 
the development of efficacious therapeutic strategies to prevent or 
delay the onset of resistance mechanism in melanoma, is fundamen-
tal. ABT888 is a potential anti-cancer drug being evaluated in multiple 
tumor types; it acts as a poly-(ADP–Ribose) polymerases (PARP) inhibi-
tor, nuclear enzymes that repairs damage to DNA. Through inhibition 
of PARP, ABT888 helps to prevent DNA repair in cancer cells, leading 
to cell death [1]. In the current study, we tested the anti-proliferative 
and pro-apoptotic action of ABT888 on the melanoma cell line A375 
resistant to B-RAF inhibitor (Dabrafenib) and on other melanoma cell 
lines.
Materials and methods: Cell viability of melanoma cell lines (A375_B-
RAFi_R, SK-MEL-5, SK-MEL-2, M14, COPA-159, A375, LOXI-IMVI, LCP, SK-
MEL-28, 397-MEL and WM-115) after 72  h treatment with increasing 
concentrations of ABT888 (5, 10, 25 and 50 μM), was evaluated by MTT 
assay; analysis of the apoptotic process was performed by the Annexin 
V-FITC assay, using flow cytometry. Cell extracts from SK-MEL-28 cell 
line were also analyzed by western blotting to evaluate the effect of 
ABT888 on the main proliferative signaling pathways.
Results: Treatment of melanoma cell lines with ABT888 caused inhi-
bition of cell growth, which was statistically significant starting from 
10 μM ABT888 (mean of 65 % of cell survival). In SK-MEL-28 melanoma 
cell lysates, ABT888 drug exhibited an anti-proliferative action by the 
inhibition of AKT as demonstrated by decreased levels of pAKT, while 
the levels of Cyclin D1 and c-Myc were not affected. In addition, 25 μM 
ABT888 treatment was able to induce apoptosis in the cells (average 
cell death equal to 34 %, by Annexin V-FITC assay), as confirmed by the 
presence of PARP-1 cleavage in SK-MEL-28 cell lysates. Furthermore, 
ABT888 showed its anti-proliferative and pro-apoptotic activity on 
A375_B-RAFi_R, by inhibition of cell growth (71 % of cell survival, fol-
lowing 10 μM ABT888 treatment) and induction of apoptosis (75 % of 
cell death, following 25 μM treatment).
Conclusions: In this study we observe that ABT888 exhibited its anti-
proliferative and pro-apoptotic activity on melanoma cell lines. Inter-
esting, we found that ABT888 was able to kill melanoma cells resistant 
to B-RAF inhibitor (Dabrafenib). This results suggest that ABT888 may 
represent a promising therapeutic approach for melanomas that have 
developed resistance against some molecular targeted inhibitors. Fur-
ther studies will be performed to assess whether the combination of 
B-RAF and PARP inhibitors can prevent or delay the onset of resistance 
mechanism in melanoma.
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Background: Cutaneous malignant melanoma is the most aggressive 
form of skin cancer, with a high mortality rate. Various treatments for 
malignant melanoma are available, but due to the development of 
multi-drug resistance, current or emerging therapies have a relatively 
low success rates. This emphasizes the importance of discovering new 
compounds that are both safe and effective against melanoma [1]. In 
the last few years, numerous physiological and pathophysiological 
roles have been proposed for the gasotransmitter hydrogen sulfide 
(H2S), along with a plethora of cellular and molecular targets. Endog-
enously, H2S is produced as a metabolite of homocysteine (Hcy) by 
cystathionine β-synthase (CBS), cystathionine γ-lyase (CSE), and 3-mer-
captopyruvate sulfurtransferase (3-MST) [2]. A number of studies have 
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investigated the role of H2S in triggering cell death and evidence has 
been presented that this gas can exert both pro- and anti-apoptotic 
activity in cultured cells [3, 4]. Recently, CBS has emerged as a poten-
tial therapeutic target in both colon cancer and ovarian cancer [5, 6]. 
The aim of our study was to evaluate the role of the metabolic H2S 
pathway in human melanoma.
Methods: We utilized cell culture, immunohistochemistry, molecular 
biology techniques and mice melanoma model.
Results: Using immunohistochemistry we demonstrated the pres-
ence of the l-cysteine/CSE/H2S pathway in human melanoma speci-
mens and provided evidence that CSE expression was highest in 
primary tumors while decreased in the metastatic lesions and it was 
almost silent in non lymph node metastases. Conversely, CBS did not 
appear to play an important role in melanoma. The role of CSE and the 
downstream signal transduction were investigated by using several 
human melanoma cell lines. The primary role played by CSE, already 
revealed by the human study, was confirmed by the finding that the 
over-expression of CSE induced spontaneous apoptosis of human 
melanoma cells (30 %; P < 0.001 vs mock transfected cells). The same 
effect was achieved by using different H2S donors and, among them, 
the most active resulted to be diallyl trisulfide (DATS) (IC50 = 89 μM). 
The main pro-apoptotic mechanisms involved were suppression of 
nuclear factor-κB activity and inhibition of AKT and ERK1/2 pathways. 
A proof of concept was obtained in vivo by using a murine melanoma 
model. In fact, either l-cysteine, the CSE substrate, or DATS inhibited 
tumor growth by 51 % and by 67 % respectively (P < 0.001, n = 8).
Conclusion: In conclusion, this work establishes that the l-cysteine/
CSE/H2S pathway is involved in human melanoma and provide the 
fundamentals to exploit a possible therapeutic/diagnostic use in this 
aggressive disease.
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Background: Revealing cancer stem cells (CSC) is a major issue for 
effective cancer therapeutics. We postulated that an immunoglobu-
lin (Ig) repertoire analysis and investigating freshly removed cancer-
ous tissues would serve this aim. Our focus was kept on the natural 
humoral immune response, having the capacity to recognize modified 
oligosaccharide expression patterns, characteristic for cancer.
Materials and methods: In the course of a tumorimmunological study 
primary and metastatic tumors as well as peripheral blood samples 
of patients with malignant melanoma (n =  123) were investigated in 
terms of antibody repertoire. Heavy (VH) and light chain (VL) Ig vari-
able region gene fragments were amplified by polymerase chain reac-
tion and VH and VL were adjoined by a [(Gly)4Ser]3 linker for the single 
chain Fv (scFv) construct. Two technical approaches for scFv phage 
display library (1) generation were standardised. A column purification 
process was used to get enriched immunoglobulins for binding assays 
(2). Comparative DNA sequence analyses and antibody phage enzyme-
linked immunosorbence assay (ELISA) with native membrane prepara-
tions were done.
Results: The expressed immunoglobulin variable region gene usage 
in the VH3 family represented the VH3-23 and VH3-21 overexpres-
sion, and revealed that sequences were frequently in a germline 
configuration with a low replacement to silent ratio of mutations. 
Among the representative Ig clusters a cancer stem cell-associated 
CD34 and GD3 disialylated glycosphingolipid-targetting pattern 
could be defined. Using native membrane preparations and primary 
cultures from the tumor was found to be ideal to reveal novel can-
cer cell characteristics and antibody fragments with CSC binding 
potential.
Conclusions: Our technology helps to understand and harness the 
miscellaneous field of human antibody repertoire composition in 
malignant diseases, compared to autoimmune and normal conditions. 
The present data show unique potentials of tumor infiltrating B cell-
derived antibodies to reveal cancer stem cell characteristics and would 
serve for novel diagnostic and therapeutic developments.
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Background: Understanding the mechanisms which contribute to the 
development of resistance to BRAF and MEK inhibitors in melanoma 
may lead to new target discovery and to the development of more 
effective combination therapies. Recently the ErbB3 receptor has been 
shown by us and by others to act as a central node in the promotion 
of adaptive survival of BRAF mutated melanoma cells early upon drug 
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exposure. Two alternative modes of ErbB3 activation have been pro-
posed: the first involves FOXD3-dependent transcriptional activation 
of ErbB3 and increased cell sensitization to exogenous ErbB3 ligand 
neuregulin (NRG1); the second increased NRG1 production and auto-
crine activation of ErbB3. The present study was undertaken to pro-
vide better insights into these two alternative mechanisms.
Materials and methods: BRAF-mutated melanoma cell lines M14, 
A375 and LOX-IMVI (BRAF V600E), WM115 and WM266 (BRAF V600D) 
were exposed to BRAFi and/or MEKi treatments at different times. 
mRNA expression levels were assessed by Real Time PCR. Western blot 
analysis was performed on total protein extracts from untreated and 
treated cells. NRG-1 in melanoma cell media was assessed using Bio-
Plex Pro NRG-1 Assays (Bio-Rad).
Results: Melanoma cells were treated with BRAFi and/or MEKi for dif-
ferent times (2–72 h) and changes in gene expression levels of NRG-1, 
ErbB3 and FOXD3 were determined. We observed two different pat-
terns. In the first case exemplified by M14 and A375 cells we detected 
simultaneous increases in mRNA levels of NRG-1, FOXD3 and (to a 
lower extent) ErbB3 only at late times after drug exposure. Surpris-
ingly, the late increase of NRG-1 mRNA expression was not accompa-
nied by increase in the secretion of the cytokine in the cell medium. 
In contrast in WM266 cells a sharp increase of NRG1 and to a lower 
extent of FOXD3 without changes in ErbB3 was observed early after 
drug exposure. In line with this last finding we were able to detect up 
to thousand –fold increase in secreted neuregulin-1 in cell media of 
WM266 shortly after drug exposure.
Conclusions: Our preliminary results show that a constant feature of 
melanoma cells exposed to drugs that inhibit the BRAF/MEK axis is the 
increased expression of NRG-1, albeit with different kinetics in different 
cells. Interestingly increased expression is not always accompanied by 
increased cytokine secretion. We are currently performing transfections 
with NRG-1 promoter luciferase fusion in order to provide new insights 
on the transcriptional regulation of this gene upon drug exposure.
P6 
HuR positively regulates migration of HTB63 melanoma cells 
Farnaz Moradi1, Pontus Berglund1, Karin Leandersson2, Rickard Linnskog1, 
Tommy Andersson1, Chandra Prakash Prasad1
1Department of Cell and Experimental Pathology, Lund University, Lund, 
Sweden; 2Center for Molecular Pathology, Institution of Translational Medi‑
cine, Lund University, Lund, Sweden
Correspondence: Chandra Prakash Prasad 
Journal of Translational Medicine 2016, 14(Suppl 1):P6
Background: HuR is a ubiquitously expressed member of the Hu 
family that contains three RNA-recognition motifs with the ability to 
bind adenylate- and uridylate-rich elements (AREs) in target mRNA 
[1]. These AREs are usually located in the 3′UTR of target transcripts, 
and the binding of HuR largely results in mRNA stabilization and/
or increased translation [2, 3]. Furthermore, aberrant HuR expression 
has been reported in malignancies such as colon, breast and pros-
tate cancer [4, 5, 6,]. Among the many established HuR targets are the 
transcripts of genes involved in cancer and inflammation, including 
COX-2 and MMP-9 [7]. Using cutting-edge PAR-CLIP technique, Leb-
edeva et al. demonstrated RBP HuR binding sites in WNT5A mRNA, in 
the transcriptome of HeLa cells [8]. Overexpression of WNT5A plays 
a significant role in melanoma cancer progression; however, the 
mechanism(s) involved remains unknown.
In the present study, we investigated if RNA-binding protein HuR inter-
acts with WNT5A mRNA thereby regulating its expression. We also 
delineated the functional consequences of such interaction by study-
ing its impact on melanoma cell migration.
Materials and methods: To identify HuR–WNT5A mRNA interaction, 
HuR-RNA binding protein immunoprecipitation (RIP) assay and WNT5A 
3′UTR luciferase assay were carried out. HuR-WNT5A association stud-
ies were investigated via siRNA knockdown of HuR and short-term 
treatment with the low molecular weight HuR inhibitor, MS-444. To 
investigate functional consequences of HuR-WNT5A interactions on 
melanoma cell migration, we performed trans-well cell migration assays.
Results: We selected HTB63 as a model cell line for our study for two 
reasons. Firstly, it expresses WNT5A protein endogenously and sec-
ondly, according to HOPP algorithm it is characterized as invasive 
cell phenotype. We found that endogenous expression of WNT5A 
correlates with levels of active HuR in these cells. We further demon-
strated that HuR protein binds to 3′ UTR of WNT5A mRNA in HTB63 
cells. HuR inhibition either via siRNA knockdown or by MS-444 treat-
ment resulted in significant inhibition of WNT5A mRNA and protein 
levels in these cells. Finally, we demonstrated that MS-444 treatment 
significantly inhibited migration of HTB63 cells in WNT5A-dependent 
fashion, as MS-444-induced inhibition was restored by the addition of 
recombinant WNT5A.
Conclusions: HuR protein binds to 3′UTR of WNT5A mRNA and gov-
erns HTB63 melanoma cell migration via up-regulating WNT5A protein 
expression.
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Background: Alterations in the properties of the basement mem-
brane are a recognized feature of cancer cells. Collagen, the principal 
structural component, must undergo appropriate post-translational 
processing for efficient function and this requires prolyl hydroxylation, 
catalyzed by the prolyl 3- (C-P3H) and prolyl 4- (C-P4H) hydroxylases, 
which have multiple family members in the human genome.
Materials and methods: Using qPCR, western blotting and pyrose-
quencing, we have investigated the expression and transcriptional 
regulation, by means of CpG Island methylation, in the C-P4H family 
in melanoma cell lines and in clinical cases of melanoma including pri-
mary and metastatic lesions, both in tissues and in sera.
To seek mechanistic correlates of the proposed differences between 
P4HA1/P4HA2 and P4HA3, we modulated expression of P4HA2 and 
P4HA3 in melanoma cell lines using ectopic expression and knock-down.
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Results: We show that the C-P4Hs P4HA1 and P4HA2 are invariably 
unmethylated and often over-expressed in melanoma, whereas P4HA3 
is subject to methylation-dependent transcriptional silencing in pri-
mary and particularly metastatic melanoma. Ectopic expression of 
P4HA2 and P4HA3 has opposing effects on melanoma growth, P4HA2 
promoting and P4HA3 inhibiting proliferation of melanoma cell lines. 
Pharmacological inhibition of C-P4H has anti-proliferative effects 
on melanoma cells irrespective of P4HA3 status and results in dose-
dependent G2-M cell cycle block. Detection of methylated P4HA3 in 
genomic DNA from the peripheral blood of melanoma patients is a 
sensitive and specific biomarker of metastatic melanoma.
Conclusions: Our data thus identify the C-P4H family as potentially 
important modulators of melanoma growth and imply that pharmaco-
logical inhibitors of collagen prolyl 4-hydroxylation merit further inves-
tigation as novel anti-melanoma therapeutics. Further, the frequent 
methylation of P4HA3 in metastatic melanoma suggests that P4HA3 
may have utility as a tissue and serum biomarker of metastatic disease.
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Background: Melanoma has a high metastatic potential due to its 
tendency to metastasize through blood and lymphatic vessels. How-
ever, to date, effective treatments for metastatic melanoma are lack-
ing and the prognosis of these patients remains very poor. One major 
goal of melanoma research is to identify new molecular targets for 
the development of novel treatments aimed to counteract intra and/
or extravasation of melanoma cells. Several studies support the role 
of the urokinase-type plasminogen activator receptor (uPAR) in mela-
noma as increased expression of uPAR has been found to be associ-
ated with poor prognosis and increased risk of metastasis [1, 2]. uPAR 
forms complex signaling units with trans-membrane receptors, includ-
ing G protein coupled Formyl Peptide Receptors (FPR)s [3]. These 
complexes lead to the activation of signaling cascades controlling 
cell migration as well as growth and survival. The uPAR84–95 chemot-
actic sequence is required to induce cell motility by interacting with 
FPRs that, in turn, signal through the integrins [4, 5]. By a drug-design 
approach based on the conformational analysis of the uPAR chemot-
actic sequence, we have developed a family of peptides which inhibit 
cell migration by preventing uPAR/FPR-1 interaction [6, 7, 8]. This study 
was aimed to investigate the contribution of uPAR on the capability of 
melanoma cells to cross endothelial barriers during metastasis with 
the aim to block this process.
Materials and methods: Human melanoma A375 and M14 cell lines 
expressing different levels of uPAR and comparable levels of FPR-1 on 
cell surface, were analyzed for their ability to move toward chemotac-
tic gradients, to invade extra-cellular matrix and to disrupt endothelial 
monolayers using the Real Time Cell Analysis System and the xCELLi-
gence technology [9].
Results: We found that uPAR levels positively correlate with motil-
ity, invasiveness and capability of human melanoma cells to cross 
endothelial monolayers. The important role of the uPAR84–95 sequence 
in determining invasive ability of melanoma cells was confirmed by 
the finding that specific antibodies recognizing uPAR84–95 as well as 
peptide inhibitors of the uPAR84–95/FPR1 interaction abrogate mela-
noma cell ability to move toward chemotactic gradients, to invade 
basal membranes and to cross endothelial monolayers.
Conclusions: These findings identify uPAR as a novel prognostic 
marker, the FPR as novel therapeutic target in melanoma and suggest 
that inhibitors of the uPAR84–95/FPR1 interaction may be useful for the 
treatment of metastatic melanoma.
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Background: Exosomes (Exo) are nanovesicles produced by tumor 
cells that regulate the intercellular signals leading to cell proliferation 
and spreading to distant sites [1]. Variable amounts of Exo produced 
within the tumor microenvironment by both malignant and acces-
sory cells also participate to enhance both migration and invasiveness 
[2] and recent studies support the role of Exo in tumor progression of 
several cancer models [3, 4]. However, their effect in melanoma pro-
gression has not been completely elucidated [5] and we explored here 
their chemotactic activity in vitro.
Materials and methods: Exo were purified by ultracentrifugation 
from culture medium of primary (LCP) and metastatic (LCM) mela-
noma cell lines. The ability of LCP and LCM to migrate was explored 
either in presence of Exo stimulation or not, using 8  μm trans-well 
chambers. Briefly, the upper chambers were filled with 104 cells in 1 % 
fetal bovin serum (FBS) Exo-free medium, whereas the lower chambers 
were filled with the same medium supplemented with LCP- or LCM-
Exo at different concentrations (10–50 μg/ml). Cells entrapped within 
the membrane were visualized after nuclei counterstaining with DAPI 
and counted at 40× magnification in at least five microscopic fields. 
Mann–Whitney test was used for statistical analyses.
Results: Not-stimulated LCP and LCM showed a similar migratory 
behaviour (13.5 ± 2.3 and 16.3 ± 2.6 cells/field, respectively) that, how-
ever, was significantly increased by stimulation with homologous Exo. 
In particular, LCP- and LCM-Exo stimulation at 10  μg/ml produced a 
2.3- and 2.7-fold-increase of the migratory capacity as compared to the 
corresponding untreated cells (p = 0.01) and this effect was apparently 
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dependent on Exo concentration (p < 0.05). Furthermore, the stimula-
tion by Exo derived from the metastatic LCM cell line provoked an 
increased number of migrated LCP cells with respect to both untreated 
cells (4.47, 5.52 and 7.96-fold increase at 10, 20 and 50  μg/ml, respec-
tively) and LCP-Exo stimulated cells (1.96, 2.19 and 2.28-fold increase, 
respectively) (p < 0.0002).
Conclusion: Although preliminary, our data appear to support the 
hypothesis that Exo released by melanoma cells enhance the chemo-
tactic activity of primary tumor cells and that this effect is mainly 
evident when using line-related or homologous Exo. Therefore, it is 
suggestive that they may have a role in tumor progression in mela-
noma in particular in favoring a metastatic phenotype.
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Background: Metabolic reprogramming is a peculiarity of tumoral 
cells. Its role in melanoma has been described but molecular actors, 
the influence of BRAF mutations on cell metabolism and molecules 
involved in bioenergetic transformation, have not been clearly 
defined.
Materials and methods: Energetic metabolism of melanoma cell lines 
with different BRAF mutational status (Table  2) was studied through 
the evaluation of oxygen consuption, ATP, lactate and ROS levels. 
Western blot analysis of subunits of mitochondrial respiratory chain 
(17 kDa, Cox IV), porin (marker for mitochondrial matrix), lactate carri-
ers (MCT1, MCT4) and MITF were also performed. Furthermore, mRNA 
levels of regulators of mitochondrial biogenesis (PGC-1alpha, PGC-
1beta), their targets (TFAM, cyt c) and HIF-1alpha were evaluated.
Results: BRAFV600 cell lines showed lower levels of MITF, PGC-1alpha/
PGC-1beta and a downregulation of oxidative metabolism related to 
a low oxygen consumption and to a higher glycolytic ATP produc-
tion, compared to BRAFwt cell lines. These latter showed an increased 
expression of HIF-1alpha (50–200 %), MCT4 (150 %) and extracellular 
lactate (about 20 %).
Conclusions: Our results highlight the existence of a specific meta-
bolic phenotype related to BRAF mutational status. These data dem-
onstrated the possibility to take into account drugs acting on cellular 
metabolism for the treatment of metastatic melanoma, in order to 
support the activity of anti BRAF/antiMEK drugs or to overcome resist-
ance mechanism.
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Background: Immunotherapy is presently providing favourable clini-
cal responses in metastatic melanoma (MM) and appears as innovative 
approach to be applied to other solid tumors. However, the thera-
peutic response is temporary and additional therapeutic approaches 
may extend its effectiveness and duration. Lenalidomide (Len) is an 
immunomodulant drug (IMiD) showing anti-inflammatory and anti-
tumor properties in several hematologic disorders [1], as well as anti-
melanoma activity in phase 2/3 clinical trials in MM [2]. Furthermore, in 
association with Sorafenib Len exerts a defined anti-angiogenic effect 
in a human ocular melanoma xenograft model [3]. As IMiD, Len acti-
vates the CD28 checkpoint expressed by T cells and drives the NF-kB 
activation downstream the p21 cell cycle negative regulator, while 
increasing the T-cell cytotoxicity. This activity occurs by overcoming 
the inhibition of CTLA4 [4]. Therefore, this study explores the molecu-
lar activity of Len against melanoma cells for future translation to clini-
cal treatment of melanoma.
Materials and methods: Three melanoma cell lines (A375, SKMEL28, 
WN266) were first cultured in serum-free medium to synchronize the 
cell cycle and then for 24 h in complete medium, supplemented with 
Len at different concentrations from 0.01 to 100 μM. A standard curve 
of cytotoxicity was assessed to measure the IC50 whereas both viabil-
ity and proliferation of melanoma cells were evaluated by MTT assay. 
The effect of Len on the cycle phases was investigated by measuring 
the DNA content by flow-cytometry after cell staining with propidium 
iodide. Finally, real-time PCR explored the RNA expression levels of p21.
Results: All three melanoma cell lines showed a threefold decrease of 
their proliferation extent by Len at 10 μM (mean values: 640 ± 30 OD 
vs 1.915 ± 15 OD, p < 0.05). However, the majority of cells were viable 
(>91 %) although frozen at the G0–G1 phase of cell-cycle (64 ± 10 %) 
with respect to untreated cells (38  ±  4.6  %). Percentage number of 
apoptotic cells was apparently similar (Len-treated: 0.7  ±  0.02 vs 
untreated: 1.7 ± 0.04 %) as well as those undergoing to S and G2-M 
phases (Len-treated: 35 ± 3 vs untreated: 60 ± 2 %). After treatment 
with Len, melanoma cell were up-regulated in their p21 RNA content 
(p < 0.01).
Conclusions: Len exerts a cytostatic effect on melanoma cell lines 
through p21 up-regulation that restrains the NFkB activity. This pro-
vides the rationale for planning further pre-clinical investigations 
exploring the Len effect on both CDK4 and CDK6 expression and activ-
ity, in order to design combination strategies with negative regulators 
of the cell cycle for the treatment of melanoma.
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Background: Harnessing the T-cell response has proven to be a suc-
cessful strategy in the prevention of tumor relapse. Recently we 
reported that Melan-A-specific CD8 T cells isolated from long-term 
surviving patients treated with DTIC before peptide-vaccination plus 
IFN-α possess higher anti-tumor reactivity and an enlarged T-cell rep-
ertoire, compared to cells isolated after vaccination alone, suggesting 
that chemoimmunotherapy may favor a protective anti-tumor specific 
immune response.
Materials and methods: To identify the mechanisms enhancing 
the immune response, we analyzed the endogenous and treatment-
induced antigen specific CD8+ T-cell response in a panel of Melan-
A- and gp100-specific clones from five patients. We analyzed the 
differentiation phenotype (CCR7 and CD45RA), the co-stimulatory 
(CD27, CD28 and ICOS) and inhibitory (TIM-3, LAG-3 and PD-1) profile, 
in parallel with the polyfunctionality (IFN-γ, TNF-α and Granzyme B) 
and activation of AKT (pSer473-AKT).
Results: Melan-A-specific T cells isolated from the endogenous 
response of both treatments showed poor polyfunctionality and low 
ICOS expression and an AKT activation status related to the differen-
tiation profile (in term of CD28 and/or CD27 expression). Conversely, 
after therapy only patients treated with combined chemoimmuno-
therapy showed tumor-specific CD8+ T cells displaying the hallmarks 
of differentiated and highly activated effector T cells. These clones 
were highly efficient in tumor killing, possessed polyfunctional activ-
ity, up-regulated inhibitory receptors, retained proliferative capability 
and activated an AKT pathway not-related to the differentiation phe-
notype and dependent on ICOS engagement. Strikingly, T-cell poly-
functionality elicited by the combined therapy was strictly dependent 
on this AKT activation, as demonstrated by the blockade with selective 
inhibitors, which occurred only in Melan-A-specific CD8+ T cells and 
not in cells specific for gp100, suggesting that the nature of the pep-
tide is crucial for the activation of this pathway.
Conclusions: We suggest that the phenotypic and functional T-cell 
signature elicited by chemoimmunotherapy is a fine-tuned balance 
between quality of the Ag/TCR complex, co-stimulatory signals such 
as ICOS, inhibitory checkpoints and AKT activation, associated with 
anti-tumor T cells that can protect patients from tumor recurrence. The 
study represents a critical contribution for the comprehension of the 
mechanisms underlying the advantages of combined chemo-immu-
notherapy and paves the way for the identification of new biomark-
ers of T-cell activation that may be employed as markers of immune 
responsiveness.
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Background: Combination therapy with BRAF and MEK inhibitors is a 
recommended treatment strategy for metastatic melanoma patients 
with BRAFV600 mutations. Combining a selective BRAF inhibitor, such 
as dabrafenib, and a MEK inhibitor, such as trametinib, has been shown 
to improve the response rate and progression-free survival in patients 
with advanced melanoma. This combination treatment results in a 
reduction in skin toxicity seen with a BRAF inhibitor alone; however, 
addition of the MEK inhibitor adds other toxicities, such as pyrexia and 
gastrointestinal or ocular toxicity. Trametinib was approved as a single 
agent for the treatment of patients with V600E-mutated metastatic 
melanoma by FDA in May 2013 and by EMA in September 2013. Later 
FDA has approved the combination of dabrafenib and trametinib for 
the treatment of patients with BRAF V600E/K-mutant metastatic mela-
noma and their use seems to be currently the best approach.
Materials and methods: From November 2013 to September 2015, 
we have collected data from 54 patients with BRAF V600E/K mutation-
positive stage IV melanoma. Patients received a combination of dab-
rafenib (150  mg orally twice daily) and trametinib (2  mg orally once 
daily). Metastatic sides were: skin (30  %), liver (28  %), lymph nodes 
(22 %), lung (15 %), brain (4 %) and spleen (1 %). Adverse events were 
monitored according to CTCAE v4.03. If dose modification was neces-
sary we used standard dose reductions as recommended by manufac-
turers. Patients were monitored every 8 weeks and therapy has been 
continued until progression or unacceptable toxicity.
Results: Among our patients no malignant and hyperproliferative 
skin lesions, interstitial lung disease, venous thromboembolism, gas-
trointestinal bleeding and heart (cardiomyopathy, decreased left 
ventricular ejection fraction) toxicities were appreciated. Evolution 
of melanocytic nevi was also assessed, none of the monitored nevi 
increased in pigmentation nor morphological changes in preexist-
ing nevi was seen following combination therapy. The most common 
adverse events (G1 grade) were fatigue (25  %) and pyrexia (23  %), 
no treatment discontinuation was necessary. Cutaneous rash (G1) 
occurred in 11 %, diarrhea (G1) and arthralgia (G1) in 5 %, ocular uveitis 
occurred in 2 % of 54 patients, but no dose modifications were neces-
sary. Severe papilloedema occurred in 1 patient of 54, that led to per-
manent therapy discontinuation. Clinically meaningful improvements 
from baseline in favour of dabrafenib/trametinib were observed for 
pain, nausea and vomiting, distress and appetite at weeks 8 already.
Conclusions: The combination of dabrafenib and trametinib was well 
tolerated and patients reported a better global health and functional 
status with less exacerbation of symptoms.
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Background: Radical lymph node dissection (RLND) is the treatment 
of choice in stage III melanoma patients. Over half of the observed 
complications were related to post-operative serum collection 
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affecting wound healing. The possibility to reduce seroma forma-
tion and the drainage permanence may offer benefits to the patients. 
The aim of the study was to evaluate the impact of this technique to 
decrease post-operative lymph output and time of drainage removal. 
This represents the first report of electrothermal bipolar vessel sealing 
system (SJ) in melanoma patients affected by nodal disease submitted 
to nodal dissection.
Methods: This was a prospective study carried out at a single center in 
which consecutive patients were submitted to radical axillary or ilio-
obturator dissection using SJ. Control group data of seroma output 
and drainage removal were obtained from a recent Author’s analyses 
published in 2012 in which were analysed patients submitted to nodal 
dissection with conventional electrocautery. Daily drainage volume 
was compared with historical control group on days 3, 10 or 15 and 
day 20. Duration of drainage was compared with historical control 
group.
Results: 70 patients with melanoma underwent an axillary or ilio-
inguinal RLND and were included in the study. The mean postopera-
tive lymph output was lower at days 3, 10, 15 and 20 than historical 
control group. About 66.6 % of patients had less of 55 cc of drainage 
at 10 days. In patients treated with SJ the mean of drainage removal 
was lower than historical control group and was 14.5 and 24.0  days 
respectively.
Conclusion: This is the first report of nodal dissection in patients with 
cutaneous melanoma performed with electrothermal bipolar vessel 
sealing system, the technique was feasible, safe, and effective. Com-
pared with historical data regarding the conventional electrocau-
tery, this technique seems to result in reduced drainage volume and 
duration of days of suction drain. Prospective randomized controlled 
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Background: Immunotherapy with immune-checkpoint molecule 
inhibitors such as anti-CTLA4, anti-PD-1 and anti-PD-L1 increases the 
overall survival of melanoma patients with or without BRAF V600 
mutations. This effect is associated with an enhanced antitumor T cell 
response. Patients with HIV infection show a high incidence of primary 
melanoma because of their immunodeficient status. No effective treat-
ment options are currently available for patients with HIV and metastatic 
melanoma and few data are available in literature for those treated with 
immune checkpoint-molecule inhibitors. Evidence suggests that both 
CTLA4 and PD-1 may play a role in HIV viral persistence as well as in the 
production of HIV-specific CD4 T cells. Here we report our recent experi-
ence in a patient with metastatic melanoma and HIV infection treated 
with ipilimumab in combination with antiretroviral therapy.
Materials and methods: A 49-year-old man was diagnosed with HIV 
AIDS in 2011. After treatment with multiple antiretroviral therapies, 
he was treated with the combination of tenofovir, emtricitabine and 
efavirence. In 2015 he was diagnosed with melanoma with multiple 
lymph node and lung metastases. Furthermore his history showed the 
diagnosis of a previous basal cell carcinoma of the back and the pres-
ence of severe anal dysplasia HPV-related. BRAF status was detected 
using the “Cobas” test. Ipilimumab was administered at 3 mg/kg intra-
venously, every 3 weeks, for four doses, starting from June 7 to August 
8, 2015. Restaging TC scan was performed on September 9, 2015. Total 
number of CD3+/CD4+/CD8+/CD16+/CD19+ cells and levels of HIV 
RNA copies were monitored during the treatment.
Results: A BRAF V600E mutation was found. No adverse events were 
reported. No significant changes were found in the number of CD3+/
CD8+/CD16+/CD19+ cells. At baseline, the number of CD4+ cells was 
296 cells/μl while the HIV RNA copies were 20/ml. An increase in the 
number of CD4+ cells and a decrease in HIV RNA copies were already 
detected after the first administration of ipilimumab. Following four 
courses of ipilimumab the number of CD4+ cells was 580 cells/μl, while 
the HIV RNA copies were not detectable. Restaging TC scan showed dis-
appearance of previous lesions and no development of new lesions.
Conclusions: Our single-patient experience demonstrates that admin-
istration of ipilimumab in HIV infected metastatic melanoma patient is 
safe and well tolerated. Furthermore it demonstrated to have a ben-
eficial effects on both HIV infection and melanoma treatment. Clinical 
trials are warranted to determine the clinical efficacy of ipilimumb in 
this setting.
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Background: Recent studies suggest that hypophysitis occurs in 
about 10–15 % of patients receiving Ipilimumab [1, 2], in contrast with 
the rarity of idiopathic autoimmune hypophysitis or hypophysitis after 
treatment with other immunotherapies [1, 3–8]. Here we present the 
case of a patient with Ipilimumab- induced hypophysitis (IH).
Case report: A 68-year-old man was admitted to our Oncology Unit 
in June 2015 with the diagnosis of metastatic melanoma. ECOG Per-
formance Status was 0 and no comorbidities were reported. In June 
2011 primary melanoma was removed surgically; during follow up, 
in May 2015, bilateral lung metastases were highlighted by CT-scan. 
Pathological lymph nodes in left axilla (more than 8  cm in diameter) 
were also reported. Ipilimumab-based therapy started in June 2015. In 
August 2015, after the third course out four scheduled doses of Ipili-
mumab, the patient referred us one-week history of heavy headache. 
No nausea, vomiting, visual symptoms, polydipsia or polyuria were 
reported. A brain MRI was performed and a pituitary swelling consist-
ent with hypophysitis was diagnosed. Haematological reports were 
consistent with hypopituitarism diagnosis: morning cortisol level 0,7 
mcgr/dl (reference range 8–25) and TSH level 0,208 UI/ml (0,250–4,5). 
Therapy with dexamethasone 4 mg IM every 6 h was started; due to 
the low decreasing THS values, levothyroxine 100 mcg once daily was 
also added. A rapid symptoms improvement was obtained by this 
therapeutic approach. The dose of dexamethasone was gradually 
decreased over 4  weeks and hydrocortisone replacement of 20  mg 
in twice daily doses has been just started. The fourth course of Ipili-
mumab was not performed because of the contemporary high-dose 
glucocorticoid therapy; furthermore, it occurred delayed liver toxicity: 
AST 160 U/L (15–46) and ALT 350 U/L (11–66). Total body CT-scan and 
brain MRI were scheduled, but a significant shrinkage in axillary lymph 
node swelling by clinical examination was observed.
Discussion: Development of IH is associated with a significant clini-
cal morbidity, so early recognition and therapeutic intervention are 
extremely relevant. Furthermore, in the absence of data demonstrat-
ing clinical benefit from high-dose glucocorticoid therapy, we won-
dered if, in absence of symptoms such as visual disturbances, there 
is the indication to start with hydrocortisone replacement therapy 
alone from the beginning [1]. We also wondered if it was reasonable 
to administer Ipilimumab during prolonged high- dose glucocorticoid 
therapy. Thus, guidelines for surveillance and management of IH are 
highly required [9, 10].
Consent to publish Written informed consent for publication of their 
clinical details was obtained from the patient/parent/guardian of the 
patient. A copy of the consent form is available for review by the Editor 
of this journal.
Page 22 of 27  J Transl Med 2016, 14(Suppl 1):S65
References
1. Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment 
and biologic insights. Pituitary. 2015. (Epub ahead of print).
2. Albarel F et al. Long‑ term follow‑ up of Ipilimumab‑induced Hypophysitis, 
a common adverse event of the anti‑ CTLA‑4 antibody in melanoma. Eur J 
Endocrinol. 2015;172:195–204.
3. Torino F, Bernabei A, et al. Thyroid dysfunction as an unintended side effect 
of anticancer drugs. Thyroid. 23:1345–66.
4. Chan WB et al. Panhypopituitarism in association with interferon‑ alpha 
treatment. Singap Med J. 2004;45:93–94.
5. Concha LB et al. Interferon‑ induced hypopituitarism. Am J Med. 
2003;114:161–3.
6. Ridruejo et al. Central hypothyroidism and hypophysitis during treatment 
of chronic hepatitis C with pegylated interferon alpha and ribavirin. Eur J 
Gastroenterol Hepatol. 2006;18:693–94.
7. Sakane N et al. Reversible hypopituitarism after interferon‑ alpha therapy. 
Lancet. 1995;345:305.
8. Tebben et al. Granulomatous adenohypophysitis after interferon and ribavi‑
rin therapy. Endoc Pract. 2007;13:169–175.
9. Juszczak A et al. Ipilimumab: a novel immunomodulating therapy causing 
autoimmune hypophysitis: a case report and review. Eur J of Endocrinology. 
2012;167:1–5.
10. Lam T et al. Ipilimumab‑ induced hypophysitis in melanoma patients: An 
Australian case series. Intern Med J. 2015. (Epub ahead of print).
Tumor microenvironment and biomarkers
P17 
New immuno‑ histochemical markers for the differential diagnosis 
of atypical melanocytic lesions with uncertain malignant potential 
Laura Marra, Giosuè Scognamiglio, Monica Cantile, Margherita Cerrone, 
Fara De Murtas, Valeria Sorrentino, Anna Maria Anniciello, Gerardo Botti
Pathology Unit, Istituto Nazionale Tumori Fondazione “G. Pascale”, Napoli, 
Italy
Correspondence: Laura Marra 
Journal of Translational Medicine 2016, 14(Suppl 1):P17
Background: For specific subsets of melanocytic proliferations, there 
are morphologic limitations in the histologic diagnosis, especially for 
borderline melanocytic tumors. [1]. In particular, Spitzoid prolifera-
tions can be difficult to diagnose. For these reasons, in the last years, 
clinic research has focused attention on discovery of new diagnostic 
markers.
Published gene expression and proteomic profiling data indicate new 
candidate molecules involved in melanoma pathogenesis, and useful 
in differential diagnosis of difficult melanocytic lesions [2,3].
Recently, the diagnostic power of galectin-3 was demonstrated in a 
series of melanocytic lesions, with a strong increasing of expression in 
malignant lesions compared with benign lesions. Similarly, the accu-
mulation of Collagen XVII antibody was detected in vertical melanoma 
fronts and associated with invasive phenotype. Moreover, overexpres-
sion of cyclin D1 and p21 was detected in Spitz nevi compared with 
non-spitzoid melanomas, Ki-67 appears highly expressed in deep 
areas of non-spitzoid melanomas [4,5]
The purpose of this study was to evaluate the expression of a panel 
of markers, suggested by literature, on a series of melanocytic lesions 
selected from our archives, to define the most useful for the differen-
tial diagnosis.
Materials and methods: We selected 56 samples from database of 
Pathology Unit of I.N.T. “G. Pascale” (Naples): 24 atypical Spitz tumor, 10 
atypical Spitz nevi, 12 primary melanomas, 5 blue nevi and 5 common 
nevi. The samples were analyzed by immunohistochemistry for the 
expression of Cyclin D1, Ki67, Galectin 3, COX2, Topoisomerase 2α, Col-
lagen XVII, GLUT1, Survivin. Ten atypical lesions and ten melanomas 
were also used for a molecular analysis to evaluate specific chromo-
somal aberrations, typical of melanoma, by FISH.
Results: Almost all of the atypical lesions showed a low proliferative 
index (<5 %), while the high expression of Ki67 is present in malignant 
lesions. The expression of cyclin D1, collagen XVII and Topoisomerase 
2α was high in borderline lesions and in melanomas with a Breslow 
thickness >1 mm and high mitotic index, and lower in common and 
blue nevi. The expression of COX2, survivin is not particularly signifi-
cant, reflecting the trend described in the literature. Only three atypi-
cal lesions showed alteration in the RREB1 locus.
Conclusions: Our preliminary data showed that Cyclin D1, the colla-
gen XVII and Topoisomerase 2α could provide useful diagnostic and 
prognostic markers for atypical lesions, being significantly overex-
pressed in invasive lesions.
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Background: Unlike other malignancies, in which measurement of 
serum tumor markers is routine, in malignant melanoma their use has 
remained far behind. The only generally accepted serological marker 
for melanoma is Lactatdehydrogenase (LDH) [1]. This study aims to 
compare the ability of three serum markers, Melanoma Inhibitory 
Activity (MIA), LDH and C Reactive Protein (CRP), to identify patients 
with melanoma. MIA serum concentration represents an independ-
ent predictor for melanoma patients’ survival [2], while an increase in 
serum CRP is considered a sign of melanoma progression [3].
Materials and methods: During January 2014–May 2015 we deter-
mined MIA, LDH and CRP serum concentrations in 100 melanoma 
patients (22-stage I, 42-stage II, 25-stage III, 13-stage IV) and 51 
healthy donors. The proteins were measured by a high sensitivity 
ELISA method. For CRP and LDH, were accepted the thresholds recom-
mended by the kit manufacturers: 5 mg/L, respectively 225 U/L. Using 
the ROC curve, MIA cut-off level was estimated at 12.5 ng/mL, value at 
which the marker has the maximum capacity to discriminate between 
healthy and melanoma subjects.
Results: MIA sensitivity is greater than that of CRP or LDH for 
stage IV (76.9  %/69.2  %/53.8  %). Conversely CRP is more sensi-
tive than MIA or LDH in identifying patients with localized disease 
(17.74  %/8.06  %/3.23  %). Taking into account the whole lot, com-
bination of CRP and MIA identifies more patients than that formed 
by MIA and LDH or LDH and CRP (40.0  %/32.0  %/30.0  %). Interest-
ingly, none of the 62 patients with localized disease had more than 
one marker above the admitted cut-off, while in stage IV at least 
one of the markers was increased in all individuals. Patients with a 
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serum MIA  >  12.5  ng/mL have a likelihood of disseminated disease 
(stage III and IV), 12 times higher than those with MIA < 12.5 ng/mL 
(OR = 12.73; 95 %CI = 3.3810−47.9148; p = 0.000169), while a patho-
logical LDH increases the probability of disseminated disease only 10 
times (OR = 10.71;95 % CI = 1.7527−65.3953; p = 0.010235).
Conclusion: Simultaneous measurement of LDH, CRP and MIA iden-
tifies a larger number of patients than measurement of any marker 
alone or any possible combination of two of them. But adding LDH to 
MIA/CRP association leads to an increase in sensitivity with only 4 %. 
Although serum LDH is used in TNM staging system, we noted that, 
even in stage IV, it has a lower sensitivity than either of the other two 
studied markers. Regarding stage IV patients, MIA/CRP combination 
has 100 % sensitivity, making LDH determination useless. We believe 
that simultaneous measurement of MIA/CRP best describes melanoma 
patients.
Source of funding Project PN-II-PCCA type 1 Nr.4/2012 (HRCarrays) 
“Array structures for prevention, individualized diagnosis and treat-
ment in cancers with high risk of incidence and mortality”
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Background: Cutaneous melanoma is a tumor with intense meta-
bolic activity that expresses and releases into blood circulation a large 
number of enzymes, cytokines and growth factors. In this study we 
aimed to identify optimal cut-off of serum melanoma inhibitory activ-
ity (MIA), a protein synthesized by malignant melanocytes. As there is 
no maximum MIA serum concentration widely accepted as the upper 
normal limit, every laboratory calculates its own cut-off value. We have 
established in a previous study a MIA threshold of 9.4 ng/mL [1]. Vari-
ous MIA cut-off values were reported in literature, ranging from 6.5 [2] 
to 17.4 ng/mL [3].
Materials and methods: During the past year, MIA serum concentra-
tion was measured by a high sensitivity ELISA method in 100 mela-
noma patients staged as follows: stage I-22, stage II-42, stage III-25 
and stage IV-13. Also, blood was collected from 51 healthy controls. In 
order to evaluate MIA ability to differentiate melanoma patients from 
healthy subjects, we plotted the ROC curve for the entire group and 
for each stage separately and estimated area under the curve (AUC).
Results: In the control group the lowest MIA value was 5.08  ng/
mL and the highest 16.35  ng/mL. In melanoma patients group, 
MIA serum concentration ranged between 4.39 and 121.29  ng/mL 
with a mean of 12.21 ng/mL and a median of 8.07 ng/mL. We have 
noticed a significant increase in MIA serum concentration in stage 
IV compared with all the other stages (p  <  0.000061 Likelihood 
Ratio). Taking into account the entire lot, the optimal ratio between 
sensitivity and specificity was found for a MIA value of 9.125  ng/
mL, same as for localized disease, but for these two categories the 
ability of MIA to separate melanoma subjects from healthy ones is 
very low, making it useless (Sn = 35.0 %, respectively 19.4 %). For 
patients with metastases the optimal cut-off was set at 12.46  ng/
mL (AUC = 0.910; p < 0.0001; Sn = 84.60 %; Sp = 86.30 %). To facili-
tate application in clinical practice, the above values were approxi-
mated to 9, 9.5 and 12.5. By raising the threshold from 9 ng/mL to 
12.5  ng/mL, MIA diagnostic efficacy for melanoma was increased 
from 33.77–43.71 %.
Conclusions: In our study a MIA cut-off of 12.5 ng/mL provided maxi-
mum diagnostic efficacy for each clinical stage compared to a cut-off 
of 9 or 9.5  ng/mL. Likelihood of having melanoma for an individual 
with MIA serum concentration greater than 12.5 ng/mL was 75 %. At 
this cut-off, MIA ability to differentiate between patients with metasta-
ses and healthy people was 84 %.
Source of funding Project PN-II-PCCA type 1 Nr.4/2012 (HRCarrays) 
“Array structures for prevention, individualized diagnosis and treat-
ment in cancers with high risk of incidence and mortality”
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Background: The molecular mechanisms responsible for the meta-
static progression of melanoma have not been fully defined yet [1, 2]. 
We have recently shown that an important role in this process is cer-
tainly played by HOX genes [2]. Regulation of HOX genes expression 
is under control of particular non-coding RNAs, some of which are 
present within the HOX locus [3]. HOTAIR is the most studied among 
them, whose aberrant expression is associated with the metastatic 
progression of many malignancies [4].
The main objective of this study was to verify the role played by HOTAIR 
in metastatic progression of melanoma and to evaluate the circulating 
levels of HOTAIR in the blood of patients with metastatic melanoma.
Materials and methods: A series of benign melanocytic/borderline 
lesions, primary melanomas pT1a/b, primary melanomas pT3/pT4, asso-
ciated with the corresponding metastases and visceral metastases, were 
selected to evaluate the potential changes in the expression of HOTAIR 
during the evolution of the disease. HOTAIR gene expression studies 
were carried out both by ISH and RT-PCR, to quantitate the expression 
levels of the lncRNA in tissues and in the serum of metastatic patients.
Results: None of the benign melanocytic lesions showed the pres-
ence of HOTAIR. The staining of HOTAIR resulted very weak in the pri-
mary pT1 lesions, while it was very strong in all pairs of primary tissues 
and corresponding metastases, with a cytoplasmic and membrane 
positivity. Surprisingly, we found the presence of HOTAIR in some 
intratumoral lymphocytes, while this positivity decreased in lympho-
cyte component further away from the tumor. HOTAIR gene expres-
sion data were similar to those obtained by ISH. Finally, HOTAIR was 
detected in the serum of all analyzed metastatic patients.
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Conclusions: These data allowed us to speculate on the fundamental 
role played by HOTAIR in the tumor evolution of melanoma. In addi-
tion, its presence in intratumoral lymphocytes could suggest that it 
may be also involved in the modulation of the tumor microenviron-
ment [5]. Finally, its detection in serum might suggests its use, as circu-
lating serum marker, in the management of melanoma patients.
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Background: Although SLNB is considered an useful instrument for 
staging, to guide treatment decisions and as entry criteria for clinical 
trials [1], some controversies remain in terms of its therapeutic benefit 
[2].
Materials and methods: The aim of the study was to evaluate the 
effect of early sentinel lymph node biopsy (SLNB) in patients with pri-
mary melanoma (≤30 days) versus delayed SLNB (≥31 days), control-
ling for all known histological prognostic parameters.We conducted a 
10-year cohort study among 748 patients who had undergone exci-
sion of the primary melanoma plus sentinel-node biopsy between Jan-
uary 1998 and December 2008 with a Breslow thickness of 1.00 mm or 
more and from the same geographic area (Lazio). Survival probability 
was estimated by Kaplan–Meier method, and prognostic factors were 
evaluated by multivariate analysis (Cox proportional hazards model).
Results: Out of the 748 patients with cutaneous melanoma, 141 
patients were SLNB positive (18.9  %) and 607 cases (81.1  %) were 
negative. Patients with positive SLNB had a higher frequency of 
melanoma with more than 2  mm of Breslow thickness (66.7 ver-
sus 31.8 %, p < 0.0001), with the presence of ulceration (26.2 versus 
15.3 %, p = 0.002), high mitotic rate (61.2 versus 32.3 %, p < 0.0001) 
and lower frequency of marked tumor-infiltration (8.7 versus 23.9 %, 
p = 0.03) than patients with negative SLNB. The frequency of nodu-
lar melanomas was also higher among patients with positive SLNB 
in comparison to negative SLNB (36.4 versus 21.0 %, p < 0.0001). No 
difference was found for sex, age, anatomic site, timing of SLNB by 
SLNB status. Ten-year melanoma specific survival was 78.7 %. Because 
a statistical interaction was observed between timing of SLNB and 
SLNB status (p = 0.002), the model was run for SLNB positive patients 
and SLNB negative patients. Among patients with positive node and 
who had undergone early dissection (≤30  days) of SLNB, 10-year 
melanoma survival was 76.5 versus 39.9  % among those who had 
undergone delayed SLNB dissection (≥31  days). After adjusting for 
sex, age, Breslow thickness, mitotic rate, ulceration and histological 
type, patients with a positive SLNB and who underwent early SLNB 
(≤30  days) had a three times decreased risk of melanoma mortality 
(HR: 0.29; 95 % CI: 0.11–0.77) in comparison with patients with posi-
tive SLNB who were underwent delayed SLNB (≥31  days). No pro-
tective effect was found for early dissection among negative node 
(HR:1.77; 95 % CI:0.97–3.26).
Conclusions: These data suggest that, among melanoma patients 
with positive SLNB, early dissection of SLNB (≤30 days) decreased mel-
anoma mortality.
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Background: 30 % of melanoma patients present high levels of psy-
chological stress and would require clinical intervention [1–2]
This study evaluates whether patients with melanoma experience:
1) anxiety, depression and distress;
2) depression, anxiety, distress and psychological distress correlated 
with each other;
3) socio-demographic factors predisposed to related psychopathology;
4) the coping strategies most frequently used to influence the anxiety, 
depression and distress experienced.
Materials and methods: To manage this study we contacted 
107 patients referred to the clinic of Dermatology of the Hospital 
“Sant’Anna e San Sebastiano” in Caserta. Fifty-five of them accepted to 
be interviewed.
The sample was composed of 29 females (47.3  %) and 26 males 
(52.7 %) with a mean age of 52.51 (52.65 male, 52.38 female).
Patients were required to fill a socio-demographic and clinical form 
inquiring about sex, marital status, education, occupation and date of 
diagnosis.
Patients were administered HADS, distress thermometer, BSI and COPE 
NVI.
Results: Women have higher scores in all scales with psychological 
distress as the more significant statistically value (p = 0.014).
About marital status and its correlation with the values of the scales 
under consideration, statistically significant results are observed for 
unmarried patients with BSI values much higher than married patients 
(p = 0.034) and with anxiety symptoms to HADS (p = 0.001). The com-
parison between the means shows that a low level of education is sig-
nificantly associated with depression symptoms HADS (p = 0.016) and 
the total score (p =  0.036). Relating the values of the scales to each 
other, we appreciated that HADS and thermometer distress corre-
lated positively (r = 0.329) whether for anxiety symptoms (p = 0.032; 
r = 0.289) or for depression (p = 0.037; r = 0.282), and BSI values cor-
relate significantly with all other scales.
Among the risk factors, such as smoking, alcohol, lack of exercise or 
inappropriate diet, those who take alcohol and live sedentarily present 
higher levels of depression (p = 0.029 and p = 0.013).
Coping Strategies (COPE-NVI): social support correlates positively 
with distress (r = 0.337), avoidance correlates positively with depres-
sion (r = 0.357), positive attitude negatively correlates with depressive 
symptoms (r  =  −0.362), problem orientation correlates negatively 
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with depressive symptoms (r = −0.484), and transcendent orientation 
positively correlates with depressive symptoms (r = 0.337).
Conclusions: Melanoma and psychopathological aspects correlate 
positively with each other, especially in relation to gender, marital sta-
tus, education, risk factors and coping styles.
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Radiation therapy contributes both immunogenic and immunosup-
pressive signals to the tumor microenvironment. Preclinical strategies 
to enhance the formers and/or mitigate the latter have demonstrated 
the concrete possibility to shift this balancing act toward a therapeu-
tic success (1). Results from preclinical experiments, in immunocom-
petent syngeneic models mimicking the setting of advanced cancer 
treated by radiation and immunotherapy have consistently found 
clinical confirmation. Particularly when combined with immune 
checkpoint blockade, radiotherapy has demonstrated to be a power-
ful adjuvant to immunotherapy. Clinical examples of synergy between 
radiation and immune checkpoint inhibitors have been reported, and 
interim results in our prospective clinical trial confirm this finding 
(2–7).
Currently, multiple clinical trials are exploring optimal combinations 
and scheduling of radiotherapy and immunotherapy. While at least 
some early evidence from these trials confirms the hypothesis that 
radiation can enhances responses to immune checkpoint inhibitors, 
in the majority of patients tumors remain unresponsive, warranting 
research to identify markers that predict response. A recent study test-
ing radiation with ipilimumab in melanoma (8) suggested that tumor 
expression of PDL-1 may predict lack of response to radiation and ipili-
mumab. However, in lung cancer patients treated with radiation and 
ipilimumab we found high PDL-1 expression among patients achiev-
ing durable complete and partial responses, without addition of PD-1 
pathway inhibitors (9). In fact, higher expression of immune check-
points has been hypothesized as a marker of more immunogenic 
tumors (10). In addition, pre-treatment mutational load has been 
found to be associated with responses to immune checkpoint inhibi-
tors (11). It will be important to determine if radiation can compensate 
tumors with a low mutational load, by inducing induce de novo T cell 
priming to multiple tumor antigens (12) and could, therefore, achieve 
responses in the absence of pre-existing neoantigens (13)
Importantly, the overall degree of immune impairment of the patients 
may be a critical predictor of response to radiation  +  immunother-
apy. For instance, we found the pretreatment neutrophil/lymphocyte 
ration might enable a priori selection of individuals with a propen-
sity to respond to the combination of radiation and GM-CSF (14). In 
another study in metastatic breast cancer patients we found that the 
impaired ability of T cells to signal in response to TCR stimulation was 
associated with a shorter progression-free survival after treatment 
with radiation and fresolimumab (Formenti et al., in preparation).
Overall, while radiation has emerged as a promising partner for immu-
notherapy, the identification of tumor and patient characteristics that 
can predict which patients should receive upfront the combination of 
immunotherapy with radiotherapy instead of immunotherapy alone 
remains unclear.
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Background: Monoclonal antibodies blocking the PD-1 immune 
checkpoint have shown promising clinical results in multiple tumor 
types, including melanoma and renal cell carcinoma (RCC) [1]. We 
previously demonstrated that PD-L1 expression on tumor cells in pre-
treatment biopsies is associated with favorable response to anti-PD-1 
[2, 3]. In melanoma, comparing PD-L1+ vs. PD-L1(−) tumors, we found 
an overexpression of genes involved in CD8+ T-cell activation (e.g., 
CD8A, IFNG) and other immunosuppressive pathways (e.g., LAG3 and 
IL10) in PD-L1+ tumors, suggesting the coordinate expression of mul-
tiple immunological factors that could influence response to anti-PD-1 
therapy. The current study in RCC was undertaken to better under-
stand why some patients with PD-L1+ tumors do not respond to anti-
PD-1 treatment.
Materials and methods: Formalin-fixed, paraffin-embedded (FFPE) 
pre-treatment tumor biopsies expressing PD-L1 were derived from 
13 RCC patients treated on four clinical trials of nivolumab (anti-PD-1) 
monotherapy at a single institution [4 responders (R), 9 non-respond-
ers (NR); RECIST]. PD-L1+ specimens were defined as those having 
≥5 % of tumor cells with cell surface PD-L1 expression by immunohis-
tochemistry (IHC) with the 5H1 mAb. RNA was isolated from PD-L1+ 
regions on FFPE slides and subjected to whole genome microar-
ray profiling and multiplex quantitative (q)RT-PCR gene expression 
analysis.
Results: In RCC specimens, (q)RT-PCR and IHC assessment of expres-
sion of candidate immune genes previously found to be up-regulated 
in PD-L1+ vs. PD-L1(−) melanomas showed that none of these mol-
ecules was differentially expressed according to clinical outcome. 
Instead, unbiased whole genome expression analysis revealed that an 
up-regulation of genes associated with metabolic and solute transport 
functions was associated with treatment failure. Conversely, PD-L1+ 
RCCs from responding patients were found to overexpress immune 
markers such as BMP1, which has been shown to positively regulate 
PD-L1 expression, and CCL3 involved in leukocyte migration.
Conclusions: Metabolic factors are a hallmark of RCC and may be 
associated with resistance to anti-PD-1 therapy. Our findings suggest 
that the general approach used to identifying markers predicting clini-
cal response to PD-1-targeted therapies, which has focused largely on 
immune modulatory receptors and ligands (e.g., PD-1, PD-L2, LAG-3) 
and T cell infiltrates, should be reevaluated. Indeed, a deeper level of 
investigation might be warranted for individual tumor types to which 
these new therapies are being applied.
Clinical trials: NCT00441337, NCT00730639, NCT01354431, NCT01358721
Supported by grants from Bristol-Myers Squibb, the National Cancer 
Institute, and a Stand Up To Cancer—Cancer Research Institute Cancer 
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Background: Cancer vaccines, including those targeting cancer/tes-
tis antigens (CTA) such as MAGE-A3, are able to induce measurable 
adaptive immune responses, but have largely failed to demonstrate 
clinical benefit in phase III studies of solid tumors. Recent successes 
of adoptive cell therapy suggest that CTA-specific T cells may act bet-
ter in the context of reinfusion after lympho/myeloablative therapy, 
due in part to immunologic benefits via lymphopenia-induced prolif-
eration of T cells, elimination of suppressive populations, and possible 
release of tumor antigens for cross-priming in hematologic diseases. 
Therefore, we asked whether combining immunization with rec-
MAGE-A3 + AS15 immunostimulant together with autologous stem-
cell transplant (ASCT) and vaccine-primed lymphocyte reinfusion 
is safe and may lead to better immunogenicity in multiple myeloma 
(MM) patients.
Materials and methods: Thirteen MM patients who achieved at least 
very good partial response after induction therapy enrolled in a pilot 
study (NCT01380145) with one recMAGE-A3  +  AS15 intramuscular 
immunization prior to ASCT followed by 7 booster immunizations 
shortly after ASCT and vaccine-primed lymphocyte reinfusion. Anti-
body (Ab) and cellular immune responses were assessed by ELISA, 
ELISpot, and intracellular cytokine staining (ICS) assays. Phenotypic 
changes in peripheral blood were assayed by mass cytometry. MAGE-
A expression was assessed in MM cells by immunohistochemistry (IHC) 
using mAb M3H67.
Results: All patients had MAGE-A  +  MM cells at baseline. All 
patients developed MAGE-A3-specific Ab by ELISA and CD4 T cell 
responses by IFNγ ELISpot, with significant expansion after booster 
vaccinations that persisted through 1  year post-ASCT. ICS con-
firmed a polyfunctional, Th1-biased CD4 T cell response (IFNγ+, 
TNFα+, IL5−) in all patients. Three of 13 patients developed MAGE-
A3-specific CD8 responses. Humoral antigen spreading was also 
observed. With a median follow-up of 31 mos, 9 patients have 
relapsed (median PFS is 27  months), one died of progressive MM, 
and one of subsequent allogeneic SCT complications. MAGE-A 
expression was assessed by IHC in seven relapse biopsies, and three 
were MAGE-A negative.
Conclusions: MAGE-A3 immunotherapy and PBL reconstitution 
induces strong Ab and Th1-biased CD4 T cell immune responses, 
and less frequently CD8 immune responses, in the setting of ASCT 
for MM. These Ab and CD4 T cell responses appear greater in magni-
tude than those seen historically in other cancers (PMID 14978137, 
26309191), despite significant immune compromise after ASCT, 
highlighting the immunologic potency of this approach. Absence 
of MAGE-A3 expression in some relapsing patients points toward 
antigen-specific immune selective pressure and suggests that com-
bination strategies aimed at limiting immune escape should be 
investigated.
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In cancers with increasing aggressiveness, cancer cells specialize 
for enhanced proliferation and cell survival. Simultaneously, they 
specialize on exploiting the host for supporting tumor growth. Con-
sequently, many of the host’s reactions are contributing to the malig-
nant behaviors of cancers. In turn, the immune system has a number 
of capabilities that have the potential of counteracting tumor growth 
and protecting the patient. Specifically, CD8+ cytotoxic T cells and 
CD4+ T helper one cells can destroy up to large tumor masses. More 
importantly, these anti-cancer T cells can provide long-term protec-
tion by keeping (minimal) residual disease in check, and patients alive 
for many years. However, in most patients T cells are dysfunctional 
and remain in a state of T cell “exhaustion”. Novel antibody therapies 
that block inhibitory receptors can lead to strong activation of anti-
tumor T cells, mediating clinically significant anti-cancer immunity for 
many years. Therapeutic interventions are now being optimized for 
enforcing anti-cancer T cell functions, and avoiding immune inhibi-
tory mechanisms of malignant diseases. Novel therapy modalities will 
likely become beneficial, provided that they help tipping the balance 
towards more activation and less inhibition of anti-cancer T cells. Care-
fully designed clinical studies with state-of-the art therapeutic and 
analytical techniques will provide detailed insight in the tumor micro-
environment of patients, and the underlying mechanisms that cause 
tumor growth or regression. Such information is crucial for the design 
of promising large-scale (combination therapy) trials.
Immunotherapy in oncology (I‑O): data from clinical trial
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Lung cancer is the leading cause of cancer-related deaths in men and 
the second leading cause in women world-wide1. Approximately 85 % 
of lung cancers are non-small cell lung cancers2, 3 and about 30 % of 
these, have a squamous histology which is associated with poorer out-
comes and limited treatment options4.
The human immune system can be an effective way of fighting cancer. 
One mechanism the lymphatic checkpoint uses, to negatively regu-
late the early stages of T-cell activation, is through expression of the 
cytotoxic T-lymphocyte antigen-4 (CTLA-4) and antibody blockade of 
CTLA-4 has been shown to increase antitumor immunity5.
In peripheral tissues, the effector phase of the adaptive immune 
response against tumor cells is partly negatively regulated through 
the binding of the programmed cell death protein 1 (PD-1) expressed 
on activated T-cells with the ligands PD-L1 or PD-L2 expressed on 
tumor cells. Tumor cells can evade the immune response through the 
upregulation of PD-L1 in tumors or the tumor microenvironment6, 
leading to immune resistance.
CTLA-4 inhibitors re-activate T-cells by blocking the deactivating 
effects of CTLA-4. PD-1 and PD-L1 inhibitors re-activate T-cell activ-
ity in peripheral tissues by blocking the binding of PD-1 to its ligand 
PD-L1. Two CTLA-4 inhibitors, two PD-1 inhibitors, and four PD-L1 
inhibitors are under development for NSCLC7.
Nivolumab recently received FDA approval for use as a single agent 
in second-line squamous NSCLC based on phase III trial data [8, 9]. 
The presentation will review available evidence for use of checkpoint 
inhibitors in advanced NSCLC.
References
1. Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung 
cancer: relevance for clinical practice and clinical trials. J Clin Oncol. 
2013;31:992–1001.
2. American Lung Association: Lung Cancer Fact Sheet [Web Page]. Available 
at: http://www.lung.org/lung‑disease/lung‑cancer/resources/facts‑figures/
lung‑cancer‑fact‑sheet.html Accessed June 12 2015.
3. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 
2008;359:1367–80.
4. McKeage MJ, Jameson MB, Investigators ASSG. Comparative outcomes of 
squamous and non‑squamous non‑small cell lung cancer (NSCLC) patients 
in phase II studies of ASA404 (DMXAA)—retrospective analysis of pooled 
data. J Thorac Dis. 2010;2:199–204.
5. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by 
CTLA‑4 blockade. Science 1996;271:1734–36.
6. Pardoll DM. The blockade of immune checkpoints in cancer immunother‑
apy. Nat Rev Cancer 2012;12:252–64.
7. Pilotto S, Kinspergher S, Peretti U, et al. Immune checkpoint inhibitors for 
non‑small cell lung cancer: does that represent a ‘new frontier’? Anticancer 
Agents Med Chem. 2014.
8. Gettinger SN HL, Gandhi L, et al. Overall survival and long‑term safety of 
nivolumab (anti‑PD‑1 antibody, BMS‑936558, ONO‑4538) in patients with 
previously treated advanced non‑small cell lung cancer. J Clin Oncol. 2015; 
April 20 (Epub ahead of print).
9. Brahmer JR, Horn L, Gandhi L, et al. Nivolumab (anti‑PD‑1, BMS‑936558, 
ONO‑4538) in patients (pts) with advanced non‑small cell lung cancer 
(NSCLC): survival and clinical activity by subgroup analysis. ASCO Meeting 
Abstracts 2014;32:8112.
